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Osteoporosis is commonly considered a women’s health problem, but is also a significant health 
concern for older men.  Less is known about the predictors of osteoporosis and bone mineral 
density (BMD) in men. The aging of the population and expected increase in osteoporosis 
prevalence makes understanding the determinants of BMD of great public health importance. 
Genetics is an important determinant of BMD, but little is known about specific loci 
associated with BMD in men and even less is known about the genetic influences on volumetric 
BMD (vBMD).  With this in mind, we investigated 4108 single nucleotide polymorphisms 
(SNPs) in 383 candidate genes for their association within a population of older Caucasian men.  
In addition, we investigated 148 of these SNPs in 28 WNT pathway genes for gene-gene 
interactions and gene-environment interactions with physical activity and body weight.   
We identified several SNPs that were associated with lumbar spine and femoral neck 
integral vBMD and explained 3.5% and 1.7% of the phenotypic variation in these traits, 
respectively.  SNPs in two genes, adenomatous polyposis coli (APC) and the homeo box A gene 
cluster (HOXA) were associated with integral vBMD at both the femoral neck and lumbar spine.  
Analysis of cortical and trabecular vBMD at the femoral neck identified SNPs that explained 
1.8% and 4.0% of the phenotypic variance, respectively. None of the SNPs for cortical vBMD 
were associated with trabecular vBMD. Statistically significant gene-gene and gene-environment 
interactions were also identified.  Of note, statistically significant interaction effects of SNPs in 
 iv
 the low density lipoprotein receptor-related protein 5 and physical activity level on integral 
vBMD at the femoral neck and lumbar spine were identified.   
Although additional work is needed to confirm and extend these findings we identified a 
number of novel associations for vBMD in older Caucasian men.  Our results suggest the 
presence of genetic loci that are skeletal-site specific and specific to either cortical or trabecular 
bone. Additionally, these findings underscore the importance of evaluating genetic variation in 
the context of other genes and environmental factors.  
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 1.0  DISSERTATION OVERVIEW AND OBJECTIVES 
Osteoporosis, a low bone mass condition that usually manifests with fragility fracture, is a global 
public health burden and serious concern for older adults.  Though more common in women, this 
condition is also present in men and can lead to permanent disability and death.  
In order to understand the factors that make an individual more susceptible to 
osteoporotic fracture, researchers often explore the correlates of BMD because of its correlation 
with bone strength and clinical utility[1-5]. Though many demographic characteristics and 
environmental factors influence BMD, genetic factors also appear to be very important. Family 
history is a significant and established predictor of osteoporosis[6] and heritability studies 
indicate that as much as 85% of the phenotypic variance in BMD may be explained by genetic 
variants[6-10].   
While genetics has been established as an important factor in determining BMD, the 
relationship is complex and many questions remain to be answered. To address some of these 
unresolved questions we sought to investigate: what genes are skeletal site specific, what genes 
are specific to the cortical and trabecular bone compartments, and if gene-environment or gene-
geneinteractions among components of the WNT signaling pathway (an important biological 
pathway in skeletal development and regeneration) are significantly associated with BMD in a 
sample of older men from the Osteoporotic Fractures in Men Study (MrOS). 
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 1.1 SPECIFIC AIMS 
 
The aim of Research Article 1 was to explore the role of genetic variation in determining integral 
volumetric bone mineral density (vBMD) of the femoral neck and lumbar spine in older 
Caucasian men.  To achieve this aim we tested for shared and skeletal site specific genetic 
effects in a two-phase candidate gene study of older men from the MrOS population study. In 
addition, we determined the amount of variation explained by significant genetic associations for 
vBMD.  
The aim of Research Article 2 was to identify genetic associations for cortical and 
trabecular vBMD of the femoral neck in older Caucasian men.  We evaluated if these genetic 
associations were unique to either the cortical or trabecular bone compartment, or were 
associated with both bone compartments.  In addition, we determined the amount of variation 
explained by significant genetic associations for the cortical and trabecular vBMD traits. 
Research Article 3 investigated genotype-genotype interactions among genes in the WNT 
signaling pathway and also investigated selected interactions between genotype and 
“environmental” factors.  Specifically, we investigated interaction effects on vBMD between 
SNPs in WNT pathway genes and physical activity as well as between SNPs in WNT pathway 
genes and body weight. 
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 2.0  INTRODUCTION 
2.1 OSTEOPOROSIS AND BONE MINERAL DENSITY 
2.1.1 Osteoporosis Epidemiology 
Osteoporosis is a condition of the skeletal system marked by low bone mass, bone fragility and 
susceptibility to fracture.  Since this condition is generally asymptomatic until a fracture occurs, 
revised definitions of disease have been developed that incorporate both fragility fractures and 
low values of bone mineral density (BMD) into the disease definition[1-3].    
 In the United States, approximately 10 million people over age 50 have osteoporosis and 
33.6 million more have low bone mass (also referred to as osteopenia)[4, 11].  Worldwide, 
osteoporosis is also a problem with as many as 30% of Caucasian women having osteoporosis at 
the hip[5].  Although BMD is used in defining osteoporosis, fragility fractures are the clinically 
significant event in the disease.   Although fracture risks vary greatly in different regions of the 
world, fragility fractures are incredibly common.  In the United States 40% of white women and 
13% of white men will experience a fragility fracture in their lifetime[2, 5, 12].  More 
specifically,  the lifetime risk of hip, spine and wrist fractures at age 50 is 18%, 16% and 16%  
respectively for white women and 6 %, 5% and 3% for white men (respectively)[12].  Estimates 
from 2000 demonstrate that fractures are also a problem worldwide with an estimated 9 million 
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 osteoporotic fractures occurring, of which 1.6 million were hip fractures and 1.4 million were 
vertebral fractures[13, 14].   
Although osteoporosis is a heterogeneous condition, epidemiologic investigation of 
disease reveals prevailing trends.  The first pattern seen is with age.  BMD increases with age 
until approximately age 30 and then begins to decline[5].  Osteoporosis prevalence markedly 
increases with an approximately seven-fold higher prevalence of disease being observed at age 
80 compared to age 50[11, 15].  Finally, age trends are seen in fracture incidence.  While many 
fractures occur in childhood, the non-traumatic, fragility fractures associated with osteoporosis 
are more common at older ages.  Specifically, beyond age 50, hip fractures generally increase 
steadily until age 75 and then decrease[14].   In contrast, a greater number of wrist and spine 
fractures occur around age 50 an then slowly decrease with advancing age[14].   
Gender differences in osteoporosis also exist.  After achieving peak bone mass, women 
have greater bone loss with age than men[16, 17].  Studies of BMD using dual energy x-ray 
absorptiometry (DXA) indicate that men have higher BMD than women, however there are 
many methodological considerations and these will be discussed further in section 2.1.5 [17-19].  
Fracture rates are higher in women than in men, which is likely a consequence of the higher rates 
of bone loss, weaker structural properties of bone and the greater likelihood of falling observed 
in women[17]. 
There is also a “clustering” phenomenon of fractures, meaning that the occurrence of one 
fracture makes it more likely that a participant will have other fractures[5, 17, 20].  In the Study 
of Osteoporotic Fractures, having had a vertebral deformity at baseline was associated with a 5-
fold increased risk of additional vertebral deformity, a 2.8-fold increased risk in hip fracture and 
a 1.9-fold increased risk in any non-vertebral fractures[21].  Additionally, a population study of 
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 residents in Rochester, Minnesota found that wrist fractures after age 35 were predictive of 
future hip fracture and vertebral fracture[22].   
2.1.2 Osteoporosis Burden and Public Health Significance 
Though low BMD is not a life threatening condition by itself, increased mortality after 
osteoporotic fracture has been observed.  Hip and vertebral fractures are associated with excess 
mortality within 5 years of fracture and there are even cautious findings of excess mortality 
following wrist fracture[20, 23].  Worldwide, the estimated disability-adjusted life-years 
(DALYs) lost was 5.8 million[14].  Hip fractures alone account for 740,000 of deaths and 1.75 
DALYs lost[14]. 
Morbidity following fracture is well documented.  Among other things, vertebral 
fractures are associated with height loss, kyphosis, back pain, fatigue, social isolation, decreased 
physical activity and negative psychological sequelae[24].  Hip fractures often result in pain, 
permanent disability, loss of mobility, negative social and psychological functioning and the 
requirement of long-term nursing care[17, 20, 23].   
Globally, osteoporosis makes up 0.83% of the non-communicable disease burden[14].  In 
the United States, direct healthcare expenditures including hospital and nursing home costs were 
estimated to be $17 billion in the year 2000.  In the United States, an individual is estimated to 
have an additional $21,000 in medical costs the first year after a hip fracture and an additional 
$1,200-$3,600 excess costs following clinical vertebral fracture[12, 20].  Although much 
attention has been paid to the economic costs of hip fracture, other fracture types also make up a 
substantial proportion of the United States’ health care expenditures[25]. 
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 The public health burden of osteoporosis is not inconsequential, but the aging of the 
population worldwide will further increase this burden.  Between 1990 and 2050, the number of 
individuals over 65 is expected to increase five-fold worldwide; all other things being equal, the 
number of hip fractures will reach 6.3 million.  A study by Burge et al. estimates that annual 
fracture costs in the United States will increase to 25.3 billion dollars by 2025 which is a 49% 
increase from 2005[26].  Such substantial increases will surely burden the health care system not 
only in terms of monetary resources expended, but also in terms of hospital and nursing home 
beds utilized.   
2.1.3 Osteoporosis in Men 
Osteoporosis is traditionally thought of as a problem of older women, and indeed, women make 
up the largest proportion of the absolute number of osteoporotic fractures in the United States 
and the world[17].   However, about one-third of all hip fractures and one half of all spine 
fractures occur in men which is a substantial number and a considerable public health 
burden[27]. 
As previously mentioned, the aging of the population is expected to markedly increase 
osteoporosis burden worldwide, and some of the greatest increases will be seen in males and the 
oldest-old (80+ years of age)[28]. This will likely mark a greater increase in osteoporosis in men 
not only because of the larger male population, but also because fractures in men typically occur 
later in life than in women.  For example, though men have a lower fracture incidence across the 
lifespan, the incidence of spine fractures begins to increase dramatically in men at age 75 and by 
around age 80, men and women have approximately the same incidence rates[27].   
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 There is evidence that the burden of OP for an individual is higher if that individual is a 
man.  Specifically men are 3 times more likely to die following a hip fracture than women, and 
utilize 4% more health care dollars than women following a hip fracture[27]. 
2.1.4 Bone Mineral Density as a Correlate for Osteoporosis 
Using fractures as the definition for osteoporosis has limited clinical utility.  The goal of defining 
osteoporosis is to identify at risk individuals before a fracture occurs, when prevention strategies 
and therapeutics can be utilized[4].   
Bone strength or stiffness cannot be directly measured in vivo, so another highly 
correlated clinical measure, bone mineral density (BMD), is used[5].  BMD, or the amount of 
bone mineral within an anatomically defined area, has been historically measured by a 
radiographic technique called dual-energy x-ray absorptiometry (DXA).  DXA uses x-ray beams 
of two different energy levels; one that is absorbed by soft tissue and one that is absorbed by 
calcified tissue[29].  These two energy beams allow the absorbance from the soft tissue 
component to then be removed from the total absorbance to get a value for bone mineral content.  
This measure of bone mineral content is subsequently divided by the cross-sectional area of the 
anatomical region to obtain a measure of bone mineral density expressed as grams/cm2. 
BMD is not only correlated with bone strength, but has also proven to be clinically useful 
in identifying those at risk of fracture[30].  BMD has proven to be highly associated with 
fracture risk, even after adjusting for other lifestyle, anthropometric and medical factors[31].  In 
white women, a one standard deviation decrease in BMD is associated with anywhere from a 1.2 
to 2.6 times higher risk of fracture[32-36].  Although less is known about the relationship in 
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 men, studies indicate that a one standard deviation decrease in BMD is associated with between a 
1.4 and 3.7 times higher risk of fracture[32-34, 36].   
Analysis of specificity and sensitivity of DXA measures, an important factor in 
determining clinical utility, has been assessed by receiver operating curves (ROC) that plot the 
sensitivity vs. 1-specificity and determine how much better a test does than chance (using a 
measure of the area under the ROC curve or AUC).  Specifically, AUCs of 0.69-0.72 were 
observed for areal BMD (g/cm2) at the hip indicating that femoral neck BMD is a useful, but not 
perfect clinical measure[34, 35].  Furthermore, analysis using ROC curves indicates that femoral 
neck and trochanteric BMD are substantially better predictors of fracture than BMD for the 
whole body or Ward’s triangle[35]. 
2.1.5 Volumetric Bone Mineral Density 
A true measurement of bone density would express bone mineral content over bone volume, but 
DXA is a 2-dimensional assessment and can only measure cross-sectional area and not the 
volume of bone.  Unlike DXA, which computes areal BMD, other measurement techniques can 
assess volume and provide volumetric bone mineral density (vBMD) measures.  Quantitative 
computer tomography of the central skeleton (QCT) or the periphery (pQCT) is being used more 
frequently in epidemiological studies to measure vBMD.    Furthermore, in vivo evidence 
indicates that QCT may be a more appropriate correlate of bone strength than DXA.  
Specifically, when excised femurs were mechanically tested for their breaking strength, 
measurements from QCT were better predictors of failure load than DXA[37]. 
Areal BMD by DXA is a two-dimensional technique that can also be confounded by bone 
size differences between individuals.  Specifically, DXA tends to overestimate BMD in larger 
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 bones[38].  This is particularly problematic when evaluating osteoporosis between individuals of 
different body size (e.g., comparisons of men and women).  DXA BMD measures show 
markedly higher BMD in men, but when vBMD, which is not confounded by bone size, is 
assessed these gender differences are less apparent[39]. 
QCT and pQCT measures can also provide more detailed bone measurements.  For 
example, bone is made up of two types of tissue; compact or cortical bone that makes up the 
outer layer and trabecular bone (also called cancellous bone) that makes up the spongy 
component on the interior of bones.  With QCT, the cortical and trabecular bone compartments 
can be resolved separately unlike with DXA. 
The clinical utility of vBMD is not yet fully understood.  However, initial findings from 
the Osteoporotic Fractures in Men Study (MrOS) demonstrate that having a low trabecular 
vBMD, a low percentage of cortical vBMD or smaller cross-sectional area at the femoral neck is 
predictive of hip fracture in older men[40].  Although these findings indicate that QCT may be 
important in the prediction of fracture, they were not superior to DXA BMD measurement and 
when used in conjunction with DXA measurements, improved prediction was not observed[40]. 
However, this was a preliminary study with only 42 fractures and follow-up work may reveal 
that differences in fracture prediction between DXA and QCT do in fact exist[40].  Similarly, in 
the Health, Aging and Body Composition Study, vertebral trabecular vBMD was a significant 
predictor of non-vertebral fracture, but was not a stronger predictor than hip BMD measured by 
DXA[34].   
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 2.2 GENETICS OF OSTEOPOROSIS 
In addition to demographic characteristics like age, family history is a well-established risk 
factor for osteoporosis indicating that genetics may play an important role in skeletal health[6].  
Additionally, there are many clinical accounts of rare skeletal conditions following a Mendelian 
inheritance pattern.  Expanding from these observations to family-based and population-based 
studies has confirmed the importance of genetics in osteoporosis and revealed some of the 
underlying mechanisms of disease. 
2.2.1 Heritability 
Heritability studies provide much of the evidence that there is a genetic contribution in 
osteoporosis risk and overall bone health.  It is relatively well documented that peak bone mass 
(as measured by DXA) is highly heritable with estimates from twin and family studies ranging 
from 40-85%[6-10].   
The heritability of bone loss is more controversial.  Early on it was noted that heritability 
was higher at younger ages.  Twin studies showed a higher heritability in younger twins[7] and a 
family study that investigated heritability across the continuum of age determined that the 
highest heritability was estimated at age 28[8].  This furthered the evidence of heritability of 
peak bone mass and one could hypothesize that environmental factors became more influential 
with advancing age.  To assess this, a few studies have examined bone loss longitudinally but 
findings have not been consistent[6, 41-45].  One study of peri- and post-menopausal women 
saw no evidence that annualized percent BMD loss was heritable at the hip, but did estimate that 
annualized percent BMD loss at the lumbar spine, whole body and forearm was about 40%[43].  
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 Although there is evidence of heritability of bone loss it is not as striking as studies assessing 
peak bone mass and there is indication within these studies that environmental factors are also 
important[6, 45]. 
Similarly, assessment of the heritability of fracture risk has been inconsistent.  Studies 
have shown that wrist fracture is heritable with estimates ranging from 25-54% [46-48], while 
other studies have shown no substantial genetic component to osteoporotic fracture[49].  A large 
twin study from the Swedish Inpatient Registry reported that the heritability of any fracture was 
only about 16%, whereas the heritability of osteoporotic fracture and hip fracture were 
substantially higher (27% and 48% respectively)[48].  Furthermore, heritability of all three 
fracture types were substantially higher for those under 69 years of age compared to older age 
groups[48].  Although there are some shared genetic components, BMD and fracture may be 
influenced by different genetic factors[46].  Further complicating the interpretation of these data, 
it is thought that there may be a genetic component to falls and frailty that are involved in 
fracture risk but distinct from those genes associated with low BMD[50]. Taken together, this 
indicates that not only are there different genetic factors regulating BMD and fracture risk, but 
that environment and possibly gene-environment interactions become more important in 
assessing the heritability of fracture risk as people age.  
As previously discussed, DXA BMD measures do not fully identify those at risk for 
fracture, are not perfect measures of bone quality, and are confounded by bone size[38].  
Therefore, other methods of assessing bone health have been identified.  These other measures of 
bone quality, which may distinguish different biological properties of bone, have also been 
assessed for heritability to determine the role of genetics.  Quantitative ultrasound (QUS) 
measures, which have been thought to more adequately represent the material properties of bone 
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 than DXA[37], have been assessed for heritability in several studies.  In general, QUS appears to 
be highly heritable with estimates ranging from 51-82%[51-53].   What is interesting is that 
although there is some overlap, 47-66% of the genetic variance explained by QUS is unique from 
the genetic variance that explains DXA measures[52-54].  Furthermore, a high genetic 
correlation between different types of QUS measures at the same skeletal site (94-99%) has been 
observed[55]. Quantitative computed tomography (QCT) measures of volumetric BMD (vBMD) 
are becoming more widely integrated into population studies as they are not confounded by bone 
size and can examine the cortical and trabecular bone compartments separately.  However, little 
is known about the heritability of these measures.  Two studies, examining vBMD using 
peripheral quantitative computed tomography (pQCT) of the axial skeleton, determined that 
heritability of cortical vBMD was between 29-42% and trabecular vBMD was between 59-
70%[56, 57].  The observation that there is a larger genetic component for trabecular vBMD 
compared to cortical vBMD is of particular interest and may prove to be biologically important.  
However, the clinical utility of pQCT measures is not yet well defined.  One study did obtain 
heritability estimates of vBMD for the lumbar and thoracic spine and found heritability estimates 
of 71% and 73% respectively for the two spine measures[58].  Although these estimates were 
substantially higher than the heritability estimates for the hip and spine BMD measured by DXA 
(43% and 56% respectively), these differences were not statistically significant[58]. 
Although these studies show the importance of genetics in determining BMD and 
osteoporosis risk, they also underscore the complex nature of this relationship.  Although 
heritability studies do not directly test this, they indicate that there is an elaborate interplay of 
genes involved in peak BMD accrual, bone structural and material properties, bone loss and 
fracture risk that influence an individual’s bone health.  Therefore, understanding the genetics of 
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 osteoporosis will likely mean understanding the genetic involvement in all of these individual 
aspects of bone health. 
2.2.2 Population-based Genetics Studies 
There are a variety of strategies used to study the role of genetics in osteoporosis.  Population-
based genetic association studies have been the most commonly employed.  To date the vast 
majority of these studies have been candidate gene studies, where a physiologically defined 
candidate gene is identified and genetic variation within this locus is tested for association with 
bone phenotypes.  A plethora of these studies have been published, but extensive work has been 
done on only a limited number of candidate genes such as the vitamin D receptor (VDR), 
collagen type 1 alpha 1 (COL1A1), estrogen receptor alpha (ESR1) and the low-density 
lipoproteinreceptor–related protein 5 (LRP5).   
Original reports identified an association between an intronic SNP in VDR and BMD at 
the hip and spine in 250 Caucasian twins[59].  However, conflicting results were observed in 
later studies with either no association detected or with associations between different VDR 
polymorphisms and BMD[60-64].   The Genetic Markers for Osteoporosis consortium 
(GENOMOS), a European consortium made up of 9 research teams at the time of the referenced 
study, published a large scale investigation of the association between VDR markers and BMD 
in 26,242 individuals[65].  This study found no evidence for association with any of the 
commonly studied VDR polymorphisms and BMD, but found a modest association between a 
SNP located at the Cdx2 transcription factor binding site and fracture and there is functional 
evidence in support of this association[62, 63, 65]. 
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 Genetic variation in the COL1A1 gene, which encodes the major protein component of 
bone, has also been associated with BMD in population-based samples.  Specifically, 
associations between BMD and variants in the proximal promoter and a mutation in the first 
intron that creates a binding site for the Sp1 transcription factor have been reported[6, 66, 67].  
The Sp1 mutation has been widely studied and functional evidence exists that the creation of this 
transcription factor binding site increases COL1A1 production[6, 68, 69].  This increase in 
production is thought to cause an imbalance between the type 1 (COL1A1) and type 2 
(COL1A2) collagen chains and result in weaker material properties of bone[6, 68, 69].  These 
findings were further supported by a large-scale investigation involving 20,786 participants from 
the GENOMOS consortium that found a lower BMD at both the hip and spine in individuals 
carrying two copies of the Sp1 mutation[70]. 
Polymorphisms in the LRP5 gene were associated with familial high bone mass and low 
bone mass (Osteoporosis-Pseudoglioma Syndrome)conditions[71, 72].  These findings led to 
further investigation of LRP5 as a biologic candidate gene and shed light on the importance of 
the  WNT/β-catenin signaling pathway inskeletal development[73-76].  Specifically, the WNT/β-
catenin pathway is thought to influence BMD through its control of bone formation by the 
regulation of osteoblast differentiation, proliferation and apoptosis[74, 75, 77].  Later work also 
found associations with common LRP5 polymorphisms and BMD in the general population and 
this finding was also confirmed in 37,534 participants from 18 research teams in the expanded 
GENOMOS consortium[78-80]. 
Technological advances have allowed for whole genome association studies to be 
completed.  Though there are a number of methodological limitations to these studies, they do 
provide a hypothesis free method of testing for genetic associations in population-based studies 
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 that are not afforded by candidate gene studies.  A genome-wide study of 2094 women from the 
United Kingdom was recently completed and promising findings from this sample were 
replicated in an additional 6463 men and women from a Dutch population-based study, and two 
additional studies of women from the United Kingdom[81].  This study identified single 
nucleotide polymorphisms (SNPs) in or near the LRP5 gene and the osteoprotegerin gene 
(TNFRSF11B) that were highly associated with lumbar spine and femoral neck BMD measured 
by DXA[81].  Another genome-wide association study of 5861 Icelandic men and women that 
validated findings in 7925 men and women from Iceland, Denmark and Australia, also identified 
TNFRSF11B as a promising gene for bone mineral density[82].  Additionally, this study 
identified the receptor activator of nuclear factor-kB ligand gene (RANKL), the estrogen 
receptor 1 (ESR1), a region on chromosome 1 and a region near the major histocompatability 
complex region (6p21) as being associated with bone mineral density.  Although these studies 
are advantageous in that they are hypothesis free, they have thus far identified previously known 
candidate genes (TNFRSF11B, LRP5, RANKL and ESR1), chromosomal regions previously 
identified by linkage studies (see Table 1 in next chapter) and explain very little of the genetic 
variation in BMD despite the high heritability estimates previously reported for BMD[83-87].  
Although genome-wide association studies have the potential to yield new insight into the 
genetic mechanisms of osteoporosis, it is unlikely that this approach alone will be sufficient to 
unravel the complex involvement of genetic factors.  More likely, the genome-wide association 
approach coupled with other population and family based studies will be needed to fill in the 
gaps of our knowledge on the genetics of BMD and osteoporosis. 
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 2.3 SKELETAL SITE DIFFERENCES AT THE HIP AND SPINE 
Although bone mineral density (BMD) measurements at the hip and spine are highly correlated 
and predictive of fractures at distal sites, there is heterogeneity between BMD measures at 
different skeletal sites and as many as 40% of patients fall into discordant diagnostic categories 
for osteoporosis when assessing BMD at both the femoral neck and lumbar spine[88-91].  
Understanding this heterogeneity would not only improve our understanding of skeletal health, 
but may help refine diagnostic criteria.  
2.3.1 Hip and Spine Fractures 
The most significant fracture types in osteoporosis are hip fractures and vertebral fractures.  
Approximately 300,000 hip fractures occur each year, and are associated with excess death, 
disability and high medical costs[1, 24].  Less commonly diagnosed and often mistakenly 
regarded as insignificant, vertebral fractures are an important component of osteoporosis 
morbidity with an estimated 750,000 occurring annually[1].  Though hip fractures are thought to 
be the most serious fracture type, vertebral fractures are also associated with decreased quality of 
life, functional impairment, pain and mortality[24, 92].   
In general, low BMD is associated with an increased risk of fracture and evidence is 
building that low BMD at individual skeletal sites may indicate fracture risk specific to that 
skeletal site [93, 94].  Ex vivo strength, measured by mechanical bending of excised cadaver 
bones, indicates that DXA measures of BMD predicted 50-60% of the failure load, or the amount 
of force a bone can withstand without breaking, at the specific skeletal site measured by DXA.  
In contrast, only 20-35% of failure load at different skeletal sites can be predicted by DXA 
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 measures[95].   Thus, bone strength is determined to some extent by skeletal-site specific 
characteristics of bone. 
2.3.2 Environmental Factors and Participant Characteristics 
BMD patterns across age differ for the hip and spine in men[96, 97].  In the MrOS study, a 5-
year increase in age was associated with a 2.6% lower areal BMD at the femoral neck but a 7.0% 
higher areal BMD at the lumbar spine[97].  This is not a gender specific phenomena and the 
increased BMD in the spine with age is thought to indicate compression fractures and osteophyte 
formation as opposed to improved strength of the spine with age[96, 97].  There is a paucity of 
information on the determinants of vBMD, but in MrOS, older age was associated with a 
decrease in integral vBMD at the femoral neck[98]. 
Anthropometric characteristics are associated with BMD measurements at the hip and 
spine.  In general, higher weight and BMI are positively correlated with both hip and spine BMD 
in men[97, 99, 100].  The influence of height is less clear.  Although some studies did not 
observe a correlation between height and BMD, others observed that taller men have lower hip 
BMD, but higher BMD at the spine[97, 99, 100]. 
Muscle strength and physical activity levels also impact BMD in men similarly at both 
skeletal sites.  In general, greater muscle strength is correlated with a higher areal BMD at both 
the hip and spine as is increased levels of physical activity[99-101].  However, there is some 
evidence of skeletal site specificity.  In the Study of Osteoporotic Fractures in Men a 1% higher 
hip BMD was observed in those with higher levels of physical activity, but no difference in 
BMD was observed for spine BMD with differing levels of physical activity[97].   Furthermore, 
there is evidence from studies in women that adding upper body exercise to a lower body 
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 exercise routine increases BMD at both the hip and spine, whereas those only doing lower body 
exercises only increase BMD at the hip[102]. 
Other lifestyle factors including smoking, alcohol use and calcium intake have also been 
examined for associations with BMD in men.  In general, lower BMD at the hip and spine is 
observed in smokers, but this finding is often not statistically significant, and is often explained 
by other health factors[97, 99, 100].  Alcohol has been found to be associated with slightly 
higher hip and spine BMD in the MrOS study, but was only associated with increased spine 
BMD in a study of older Finnish men[97, 99, 103].  Skeletal site differences have been 
consistently observed in relation to calcium intake and BMD.  Men with higher calcium intake 
have higher hip BMD, but no difference in spine BMD is detected[97, 99, 100].  Free 
testosterone has been shown to be an independent predictor of hip BMD, but is not associated 
with spine BMD[104]. 
2.3.3 Genetic Factors 
There is indication that heritability of BMD may be skeletal site-specific.  Specifically, 
heritability assessment of premenopausal women and their children indicated distinct genetic 
mechanisms regulating the lumbar spine and femoral neck despite a high correlation of these 
phenotypes(105).  Specifically, this studyidentified higher correlation between mothers and 
offspring at the same skeletal than across skeletal sites(105).  Furthermore, genetic correlations 
between the lumbar spine, femoral neck and whole body indicate that the loci affecting the 
lumbar spine are more likely to affect total body BMD than are those loci affecting the femoral 
neck[106]. 
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 Several whole genome linkage studies examining BMD have been completed, and eight 
of these studies that examined both hip and spine BMD in the same set of participants were 
evaluated to see if similar linkage signals were observed at both skeletal sites (Table 2)[83-85, 
107-111].  Although associations between the same chromosomal locations for the same trait 
 
Table 2-1 Summary of Linkage Scores by Chromosomal Locations for Studies Investigating Lumbar Spine 
and Hip Bone Mineral Density 
 
 
were detected, detecting associations with different skeletal sites in the same chromosomal 
region was less common.  No individual study identified the same region as being associated 
with both spine and hip BMD, but the lumbar spine and femoral neck were associated with the 
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 1q21-23 region in the Ralston[109] and Koller[107] studies, and the 7p14 region in the 
Ralston[109] and Shen[110] studies.  It is likely not a coincidence that the Ralston study[109] 
appears in both of these cases.  This study was by far the largest, and would have had the highest 
power to detect significant association signals.  The lack of overlapping linkage signals for 
different skeletal sites adds support to the notion of skeletal site specific genetic regulation.  The 
minimal overlap between QTLs for different BMD measures in this investigation is certainly in 
line with the heritability studies done to date[105, 106].    
A recent meta-analysis of genome-wide linkage studies for BMD, compared associations 
within discrete regions of the genome (referred to as bins) and different skeletal sites[112].  No 
individual bins were associated with both femoral neck and lumbar spine BMD, but when the 
bins were ranked in terms of their significance level for each trait there was a correlation 
between ranking of lumbar spine bins and femoral neck bins[112].  This further supports the 
hypothesis that although may also be some genetic factors that act on BMD globally, there may 
be many site-specific genetic factors. 
2.4 COMPARTMENT SPECIFIC DIFFERENCES 
There are two compartments of bone, the trabecular (or spongy) bone compartment and the 
cortical (or compact bone) compartment.  The physiology and structure of these two types of 
bones fundamentally differ and many of the factors that influence the density of these two bone 
compartments also differ. 
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 2.4.1 Environmental and Participant Characteristics 
Different age patterns have been observed in trabecular and cortical bone.  In the Study of 
Osteoporotic Fractures in Men, age was associated with a sharp (22%) decrease in trabecular 
vBMD across the age range of the study, but there was no association with cortical vBMD at the 
femoral neck[98, 113].   However, studies of compartment specific vBMD of the peripheral 
skeleton show age decreases in both trabecular and cortical vBMD but at different rates[57, 114].  
Furthermore, a cross-sectional study examining a larger age rangge (20-90 years) showed a 
significant decrease in both cortical and trabecular vBMD at the femoral neck in men[115].  
However, a much larger percent decrease was seen in trabecular vBMD than in cortical vBMD 
for men (45% vs 13%) in that cross-sectional study[115]. 
Data from the MrOS Study indicate that there are differences in anthropometric correlates 
of vBMD in different compartments.  Specifically, higher weight was associated with higher 
vBMD for both compartments in the femoral neck, but weight change since age 25 was only 
associated with cortical vBMD[113].  A study of correlates of pQCT measures in Afro-
Caribbean families identified weight as an important correlate for both compartments, but in 
different directions, with weight being positively correlated with trabecular vBMD and 
negatively correlated with cortical vBMD[57].  Though height was not associated with cortical 
vBMD in the MrOS Study, both height and change in height since age 25 were associated with 
trabecular vBMD[113].  Similarly, pQCT findings have indicated that height is negatively 
associated with trabecular vBMD but that there is no association with cortical bone[57]. 
In a study of younger men, physical activity was associated with higher trabecular vBMD 
at both the tibia and radius but there was no difference in cortical vBMD at the tibia and a 
slightly lower cortical vBMD at the radius[116].  In contrast, data from a population of older 
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 men from the MrOS study observed no difference in vBMD from either compartment at the 
femoral neck[113].  However, better muscle strength, as measured by grip strength, was 
associated with higher cortical and trabecular vBMD at the radius[114]. 
Smoking was not associated with vBMD in either compartment at the radius, but was 
associated with a lower trabecular vBMD at the femoral neck[113, 114].  Another study 
examining correlates of pQCT indicates that smoking is associated with lower trabecular vBMD 
but no difference in cortical vBMD at either the radius or tibia [57].  Alcohol use was not 
associated with trabecular vBMD, but was positively associated with cortical vBMD at the 
femoral neck [113].  Higher dietary calcium intake was associated with higher trabecular vBMD 
but was not associated with cortical vBMD at the femoral neck[113]. 
2.4.2 Genetic Factors 
Differences in trabecular and cortical measures have been observed in inbred mouse strains[117, 
118].  Specifically, cortical thickness was shown to differ in a variety of mouse strains[118].  
Cortical and trabecular microCT measures differed in three strains of mice previously classified 
as having high, average and low BMD[119].  A linkage study, investigating differences when 
bones were mechanically loaded in mice, identified some loci that were independently associated 
with cortical vBMD but not total vBMD at the same skeletal site[117].  However, this study did 
not explicitly examine trabecular vBMD[117].  Other studies investigating  trabecular traits in 
mice identified linkage peaks that were distinct from total BMD at any skeletal site[120]. 
Cortical and trabecular vBMD are highly heritable but there may be a lower heritability 
for cortical vBMD (17-42%) than trabecular vBMD (59-73%)[56, 57, 121].  A study by Wang et 
al., of Afro-Caribbean families, examined the genetic correlation between compartment and 
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 skeletal site specific pQCT measures at the radius and tibia[121].  This study found a high 
correlation within compartments at different skeletal sites (genetic correlation with trabecular 
vBMD measures was 0.87 and with cortical vBMD measures was 0.83) but not across 
compartments within the same skeletal site nor across compartments and across skeletal sites 
(genetic correlation ranged from 0.25-0.32)[121].  Collectively, the evidence from mouse and 
human studies indicates that although there may be some overlap, distinct sets of genes may 
influence cortical and trabecular vBMD. 
2.5 GENE-ENVIRONMENT INTERACTIONS 
Genes function in the context of environments and it is important to consider the influence of 
environmental factors in the study of complex genetic traits like BMD[122]. Gene-environment 
interaction occurs when genotypic and environmental effects differ depending on the 
environment a genotype is in[123].  Gene-environment interactions may be an important avenue 
of research for prevention and treatment in the anticipated era of personalized medicine[124]. 
Examples of gene-environment interactions exist for bone mineral density[125, 126].  
Interactions between taking hormone replacement therapy and genetic variation in both the 
interleukin 6 gene (IL6) and the estrogen receptor 1 gene (ESR1) are associated with BMD[127-
129].  Genetic variation in IL6 was also associated with hip BMD in those receiving insufficient 
dietary calcium, but not in those with adequate calcium[128].  Low birth weight, a marker of 
poor gestational nutrition, may interact with vitamin D receptor (VDR) genotype to influence 
BMD at the lumbar spine[20].  Although investigating gene-environment interactions is 
methodologically complex, requires large samples sizes to achieve sufficient statistical power 
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 and involves carefully characterization of environmental factors of interest, these studies are 
worthwhile because of their potential to identify important biological relationships in 
osteoporosis. 
2.6 GENE-GENE INTERACTIONS 
In both human and animal genome-wide linkage and association studies, the main effects 
identified fail to account for the amount of variation in bone related traits that we would expect 
to explain based on the findings from heritability studies.  However, a more thorough 
understanding of the genetics of complex traits such as BMD will also likely require insight into 
how genetic variants interact with each other to influence the variation in a trait.  In other words, 
having the presence of two or more genetic variants associated with low BMD may not result in 
a lower BMD that is reflective of an additive effect of these two variants.  Knowledge of gene-
gene or epistatic interactions may not only be important in explaining the variation in BMD, but 
increased knowledge of these interactions may shed light on the underlying biology that impacts 
skeletal health. 
2.6.1 Animal Studies 
Studies of inbred mouse populations are often used to examine epistatic effects because their 
breeding can be so tightly controlled and the genotypes of the parental generation are known.  A 
genome-wide linkage study of mice from an F2 cross between the inbred strains MRL/MpJ and 
SJL/J identified several significant gene-gene interactions for both femoral breaking strength and 
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 femoral BMD[130].  These interactions explained a substantial amount of the variation in the F2 
generation with 14.6% of the variance observed for femoral breaking strength being explained by 
3 locus-locus interactions, and 17.8% of the variation observed for femoral BMD being 
explained by 2 locus-locus interactions[130].  Another study that crossed Fischer 344 and Lewis 
F2 rats identified several locus-locus interactions for a variety of skeletal sites and both 
volumetric and areal BMD[131].  As much as 17% of the phenotypic variation at a given skeletal 
site was explained by significant epistatic interactions in this study[131].  However, not all 
studies indicate that there are significant epistatic interactions for BMD.  One investigation that 
crossed C57BL/6J and C3H/H3J mice, which differ in femoral and lumbar spine BMD by 51% 
and 9% respectively, found virtually no evidence of gene-gene interactions in the progeny and 
concluded that the loci contributing to BMD are largely independent[132]. 
2.6.2 Human Population and Family-based Studies 
Though often more complicated and costly, investigations of gene-gene interactions are not 
limited to animal studies.  One example is a genome-wide linkage analysis of 451 families 
having at least one member with low BMD[133].  In this investigation, loci strongly or 
moderately associated from main-effects analyses were used to test for epistatic interactions and 
though no significant interactions for hip BMD were observed, two locus-locus interactions for 
spine BMD were identified[133].  These investigators also completed a study of 20 candidate 
genes in which a significant interaction between three pairs of genes was observed[134].  The 
authors note that one pair of genes, the glucocorticoid receptor (GCR) and the estrogen receptor 
2 (ESR2), have been shown to biologically interact and counteract each other in their regulation 
of bone metabolism[134].     
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 The two studies above were completed as parts of larger association and linkage studies 
and focused on significant main effects to guide the inclusion of genes in the interaction analysis.  
Another approach to assessing gene-gene interactions would be to identify a set of genes that are 
thought to interact biologically based on molecular biology investigations, and then interrogate 
these findings for interactions regardless of whether or not they had important main effects.  One 
example of this approach was a study of 434 families which sought to determine if genetic 
variants in the COL1A1 gene, an important candidate gene for BMD that makes up the major 
protein component of bone, interacted with 11 genes thought to regulate osteoclast 
differentiation[135].  Although this study identified several loci that were significantly associated 
with BMD at the femoral neck without interacting with other genes, IL6 and TNFRSF1B were 
only significant when epistatic effects with the COL1A1 gene were taken into account[135]. 
Altogether these studies demonstrate the importance of genetics in determining BMD, but 
underscore the complexity of this relationship.  Building from these studies we hope to explore 
the genetic factors associated with volumetric BMD in older Caucasian men. 
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 3.1 ABSTRACT 
Genetics is a well established but poorly understood determinant of bone mineral density 
(BMD).  While some genetic variants may influence BMD throughout the body, others may be 
skeletal site specific.  We initially screened for associations between 4608 tagging and 
potentially functional single nucleotide polymorphisms (SNPs) in 383 candidate genes and 
femoral neck and lumbar spine volumetric BMD (vBMD) measured from quantitative computed 
tomography scans among 862 community-dwelling Caucasian men aged ≥65 years in the 
Osteoporotic Fractures in Men Study (MrOS).  The most promising SNP associations (P<0.01) 
were validated by genotyping an additional 1156 Caucasian men from MrOS.  This analysis 
identified 8 SNPs in 6 genes (DMP1, APC, HOXA, PTN, FGFR2 and FLT1) that were 
associated with femoral neck vBMD and 13 SNPs in 7 genes (APC, BMPR1B, FOXC2, HOXA, 
IGFBP2, NFATC1, SOST) that were associated with lumbar spine vBMD in both genotyping 
samples (p<0.05).  Although most associations were specific to one skeletal site, SNPs in the 
APC and HOXA gene regions were associated with both femoral neck and lumbar spine BMD.  
The current analysis identifies several novel and robust genetic associations for volumetric BMD 
and these findings in combination with other data suggests the presence of genetic loci for 
volumetric BMD that are at least to some extent skeletal-site specific.    
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 3.2 INTRODUCTION 
Osteoporosis, a condition marked by low bone mineral density (BMD) and an increased risk of 
fracture, is a significant health burden in older individuals(1).  Hip and vertebral fractures are 
major osteoporotic fractures and occur in approximately 300,000 and 750,000 individuals, 
respectively each year(2,3).  Although osteoporosis is more common in women, it is also a 
substantial problem among older men. In contrast to our understanding of osteoporosis in 
women, considerably less is known about the etiology and prevention of osteoporosis in men. 
Genetic factors have an established influence on BMD, with heritability estimates 
indicating that as much as 85% of the population variance in BMD is due to genetic variants (4) 
and that some of these variants may be skeletal site and sex specific(5).  Identification of 
individual genetic variants by candidate gene association studies has had some success, but many 
studies have been limited because they characterized a single candidate gene at a time, did not 
comprehensively investigate genetic variation for the candidate gene of interest and did not 
validate findings in an independent sample.  Further complicating the search for genetic factors 
contributing to BMD, many studies have had small sample sizes and/or had potential design 
flaws, such as failing to account for population stratification.   Recently, genome-wide 
association studies have been completed to identify genetic variants that influence dual energy 
X-ray absorptiometry (DXA) measures of areal BMD(6,7).  Although these genome-wide studies 
have identified several genetic loci of interest, the loci identified explain very little of the 
variation in BMD(8-12).  Thus, much of the genetic variation in BMD remains to be explained. 
Further, the majority of genetic investigations have measured areal BMD by DXA which is 
confounded by bone size and may be increased erroneously at the lumbar spine by spinal 
degenerative disease and aortic calcification(13-17).  Volumetric BMD (vBMD) measured by 
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 quantitative computed tomography (QCT), avoids some of the limitations of DXA, but to date, 
little is known about the genetic determinants of vBMD. 
In the current study, we assessed and subsequently validated the associations between 
common genetic variation in 383 biological candidate genes and vBMD of the femoral neck and 
lumbar spine among 2,018 older Caucasian men in the Osteoporotic Fractures in Men Study 
(MrOS).   
 
3.3 METHODS 
3.3.1 Study Participants 
Participants for this investigation were selected from the Osteoporotic Fractures in Men Study 
(MrOS).  MrOS is a prospective, cohort study designed to investigate anthropometric, lifestyle 
and medical factors related to bone health in older, community dwelling men.  At study entry, 
participants were at least 65 years old, community-dwelling, ambulatory and had not had 
bilateral hip replacement(18).  In total, 5995 men were recruited from March 2000 through April 
2002 primarily using population-based mailings in 6 geographic regions in the United States: 
Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Pittsburgh, PA; Portland, OR and San 
Diego ,CA(19). 
Caucasian participants with volumetric bone mineral density (vBMD) were selected for 
genotyping in the current investigation if they had not reported taking bone altering medications 
such as androgens, anti-androgens or oral corticosteroids and had not reported being on 
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 osteoporosis treatment.  Genotyping was completed in two phases using two independent 
samples from the MrOS cohort: a discovery sample and a validation sample.  Specifically, the 
discovery sample was comprised of 862 Caucasian men with lumbar spine or femoral neck 
vBMD measures.  These men were selected without regard to their BMD level from the 
Minneapolis and Pittsburgh clinic sites for genotyping.  Promising SNPs identified in the 
discovery sample were then tested for replication in 1156 additional men with vBMD measures 
in a validation sample that was comprised of men from the remainder of the MrOS clinic sites 
(Birmingham, Palo Alto, Portland and San Diego). 
3.3.2 Volumetric BMD 
Volumetric BMD (vBMD) was measured using quantitative computed tomography (QCT) of the 
hip and lumbar spine.  Due to cost restraints, only the first 65% of the MrOS cohort and all non-
white participants were referred for QCT scans. There were few differences between the men 
who did and did not receive QCT scans except that those with QCT scans were slightly younger 
and more likely to be from a minority population(20).  
 QCT measurement of the lumbar spine was obtained using an anatomical region 5mm 
above the L1 superior endplate to 5mm below the L2 inferior endplate and hip scans were 
obtained in the anatomical region defined by the femoral head to 3.5 cm below the lesser 
trochanter.  Lumbar spine images were acquired using settings of 120 kVp, 150 mA, 1-mm slice 
thickness and 512x512 matrices. For this the region of interest was the second lumbar vertebra 
excluding the transverse processes.  Hip images were acquired at settings of 80 kVp, 280 mA, 3-
mm slice thickness, and 512 x 512 matrix in spiral reconstruction mode.  The femoral neck 
region was defined as the region from the minimum cross-sectional area to the point 25% 
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 towards the maximum cross-sectional area where cross-sectional area was measured along the 
neutral axis.  Different scanners were used at different clinic sites.  Specifically, the images were 
acquired on a GE Prospeed at the Birmingham clinic, a GE Hispeed Advantage at the 
Minneapolis clinic, a Philips MX-8000 at the Palo Alto clinic, a Siemans Somatom +4 at the 
Pittsburgh clinic, either a Phillips CT-Twin or Toshiba Acquilion at the Portland site, and a 
Picker PQ-5000 in San Diego.   
 QCT images were processed (by TFL) at the University of California at San Francisco 
using a standardized protocol.  Each participant scan included a calibration standard of three 
hydroxyapatite concentrations (150, 75 and 0 mg/cm3) and these were used to convert between 
Hounsfield units and vBMD.  Differences between the clinic sites exist and are statistically 
adjusted for in all analyses.  
3.3.3 Other baseline characteristics 
Participant characteristics including age, race/ethnicity, health history and medication use were 
obtained by a self-administered questionnaire.  Physical characteristics were obtained by clinic 
staff.  Height was measured by Harpenden stadiometer and weight was measured by balance 
beam scale. 
3.3.4 Candidate Gene and Single Nucleotide Polymorphism (SNP) Selection 
Physiologically defined candidate genes were identified from publicly available resources. 
Specifically, literature searches were conducted using Pubmed, evidence of gene expression in 
normal human trabecular bone cells was obtained from the Skeletal Gene Database 
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 (sgd.nia.nih.gov, no longer available) and the NCBI UniGene database 
(www.ncbi.nlm.nih.gov/sites/entrez?db=unigene), genes with functions of interest (e.g.,  
“regulation of bone mineralization” or “skeletal development”) were obtained from Entrez Gene 
(www.ncbi.nlm.nih.gov/sites/entrez?db=gene) and Amigo (amigo.geneontology.org/cgi-
bin/amigo/go.cgi), genes with a skeletal phenotype in mice were identified from the Jackson 
Laboratory Mouse Genome Informatics database (http://www.informatics.jax.org/) and the 
Online Mendelian Inheritance in Man database (www.ncbi.nlm.nih.gov/omim/) was queried for 
evidence of genes implicated in skeletal conditions in humans.  In total, 383 candidate genes 
were identified for genotyping (Table 3-1). 
Publicly available databases were then interrogated for SNP variation in the region 
surrounding the candidate gene.  For the first phase of genotyping (the discovery sample) two 
SNP selection strategies were utilized.  In the first strategy, genetic variation in the region 
spanning 30kb upstream and 10kb downstream of each candidate gene was captured by creating 
a reference SNP panel of variants with a minor allele frequency (MAF) of at least 5% in Phase I 
of the International HapMap Project (www.hapmap.org)(21). Tag SNPs were then selected using 
a pair-wise correlation method (r2 ≥0.80)(22).  Candidate genes that were clustered near each 
other on the chromosome were tagged as a unit spanning all loci of interest. For example, 
IGFBP2 and IGFBP5 are located only 7.6kb from each other on chromosome 2.  Since the region 
of interest for these two candidates overlapped they were tagged as a unit.  In the second 
strategy, potentially functional SNPs that were either non-synonymous coding variants, predicted 
to alter a putative transcription factor binding site in the promoter region, or a putative exon 
splice enhancer with MAF ≥1% were selected for genotyping using the PupaSNP 
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 (pupasuite.bioinfo.cipf.es/) and Promolign (polly.wustl.edu/promolign/main.html) 
databases(23,24).   
Genotyping for the second phase of the project was conducted in a validation sample for 
promising SNP associations identified from the discovery sample.  Specifically, SNPs with a p-
value ≤0.015 for either femoral neck or lumbar spine vBMD in the discovery sample were 
genotyped in the validation sample.  Additionally, SNPs with a p-value ≤0.05 in a gene that also 
had a SNP with p-value ≤0.015 in the discovery sample were included in the second phase of 
genotyping.   
3.3.5 Genotyping 
Genomic DNA from frozen whole blood specimens was extracted using the Flexigene protocol 
(Qiagen; Valencia, CA).  Genotyping was completed using the Illumina Golden Gate custom 
assay.  For the discovery sample, 37 participant samples were run as blind duplicates and 4 
internal controls were included per plate to ensure reproducibility.  We observed 100% 
reproducibility among the internal controls and 99.9% reproducibility among replicate 
participant samples.  In the validation sample, 26 participant samples and 4 internal controls per 
plate were included for quality control. We observed 99.9% reproducibility among internal 
controls and among duplicate participant samples.  To ensure maximum genotyping 
completeness in the validation sample, loci of interest that could not be genotyped using the 
Illumina Golden Gate assay were genotyped using one of two platforms: the TaqMan allelic 
discrimination assay system (Applied Biosystems, Foster City, CA) on a 7900HT Real-time PCR 
instrument with probes and reagents purchased from Applied Biosystems or Sequenom 
MassARRAY iPLEX Gold technology (Sequenom, Inc; San Diego, CA) with PCR primers 
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 purchased from Invitrogen (Carlsbad, CA).  Participant samples were run in duplicate for these 
platforms and an average reproducibility of 99.8% and 99.9% was observed for TaqMan and 
Sequenom, respectively.    
 Loci with a minor allele frequency less than 1% in the genotyping sample (N=129), that 
did not conform to the expectations of Hardy-Weinberg equilibrium (P<0.0005; N=123) or that 
had a low call rate (<85%; N=241) were excluded from statistical analysis.  Individual samples 
with a low call rate (<85%) (N=14) or that were highly correlated with another sample 
(indicating relatedness; n=13) were excluded from the analysis.  
3.3.6 Statistical analysis 
Although only Caucasian individuals were investigated in this study, population stratification is a 
potential concern in large-scale genomic analyses(25).  Stratification was initially assessed using 
the program Structure.  Structure is a model-based clustering program that parses the participants 
into sub-populations and assesses if there are distinct populations or admixed individuals(26).  
We found little evidence of population stratification in the discovery, validation or pooled 
samples.  Nevertheless, we accounted for potential fine scale population sub-structure by 
employing a principal components method of analysis using uncorrelated SNPs (r<0.2) to 
calculate the principal components (27).   
Analyses of association between genotype and vBMD assumed both an additive and 
recessive model of inheritance.  Linear regression was used to test for an additive association 
between the number of copies of the minor allele and vBMD.  For the recessive model, 
regression methods were implemented to determine if individuals having two copies of the minor 
allele differed from those with the other two genotypes.  SNPs with 10 or less individuals having 
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 the rare genotype were not tested for the recessive model to minimize spurious findings based on 
small genotype specific sample sizes.  All analyses adjusted for patient age and clinic site in 
addition to the first principal component of the population sub-structure analysis.  SNPs with 
associations (p<0.05) in both the discovery and validation sample and that also had the same 
direction of association (regression coefficient + or - for both genotyping samples) were 
considered to be replicated.  Therefore, although we did not use a strict Bonferoni p-value to 
adjust for multiple-testing in the discovery sample, we conservatively required that the same 
SNP had an equivalent, significant (p<0.05) effect in the validation sample to be considered a 
replication.   
Replicated SNP associations were examined further in the pooled sample of 2018 
individuals from the discovery and validation samples.  In addition to the analyses described 
above, further adjustment for height and weight was conducted in the pooled sample to 
determine if body size attenuated the relationship between genotype and vBMD.  Linear 
regression analysis was used to determine the amount of phenotypic variation explained by all of 
the significant (replicated) SNPs.  Since SNPs in the same gene region are often correlated, the 
colinearity of individual SNPs in the model was assessed.  One pair of SNPs in the femoral neck 
analysis and three in the lumbar spine analysis were highly correlated and in those instances the 
SNP with the most missing genotypes was dropped from the regression modeling of all 
significant SNPs. 
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 3.4 RESULTS 
The average age of men in the pooled analysis was 74 years (range, 65 –100 years).  The men in 
the discovery and validation samples were similar in age. Men in the validation sample had 
lower body weight, lower BMI, taller stature and had slightly lower lumbar spine and femoral 
neck vBMD (p<0.001 for all) (Table 3-2). 
In the discovery sample, 4108 of 4608 attempted SNPs passed quality control criteria and 
were analyzed for their association with lumbar spine and femoral neck vBMD.  The mean SNP 
density for candidate genes was 1 SNP per 13.2 kb (range; 1 SNP/3.2 kb – 1 SNP/97 kb).  Tag 
SNPs were selected based on Phase I of the International HapMap Project.  Nevertheless, the 
SNPs included in our analysis tagged on average 64% (range per gene, 1%-100%) of the SNPs 
with a MAF >5% in phase II of the International HapMap project.  Of the SNPs captured by our 
tag SNP set, the mean max r2 was 0.97.   
193 SNPs in 56 genes were associated with femoral neck vBMD and 173 SNPs in 59 
genes were associated with lumbar spine vBMD in the discovery sample and were subsequently 
genotyped in the validation sample (Figure 3-1a and 3-2a).   For the femoral neck, there were 
several SNPs that had significant p-values in both the discovery and validation samples, but the 
direction of association was not the same in the two samples.  Specifically, this occurred for one 
SNP in PAX3 (rs1367408), IRAK2 (rs779905), EGFR (rs2075109), CYP17A1 (rs12219246), 
IGF1R (rs3784606) and BMP7 (rs6127983) and for two SNPs in CDK6 (rs2374589 and 
rs3802073) (Figure 3-1b).  8 SNPs in 6 genes (DMP1, APC, HOXA, PTN, FGFR2 and FLT1) 
were associated with femoral neck vBMD in both the discovery and validation sample and the 
association was in the same direction (Table 3-3). The strongest SNP association with femoral 
neck vBMD in the pooled analysis was with rs4705573 in APC (p=0.001).  Men who were 
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 homozygous for the minor allele (GG genotype) of this SNP had a 3.4% lower vBMD then men 
homozygous for the major allele (AA genotype).  Although rs1381632 in DMP1 was significant 
in both the discovery and validation sample, different genetic models were significant and 
consequently the pooled analysis was not significant (p=0.0961).  Additional adjustment for 
weight and height did not attenuate any of the SNP associations for femoral neck vBMD (Table 
3-3).    Each SNP only explained a small amount of the variation in femoral neck vBMD in the 
pooled sample (0.1%-0.5%; see Table 3-3).  The two SNPs in APC (rs6594646 and rs4705573) 
were in linkage disequilibrium (LD) (r2=0.979 and D’=0.991) and rs6594646 was consequently 
dropped from the regression modeling.   The 7 replicated SNPs in APC, DMP1, FGFR2, FLT1, 
HOXA and PTN included in the regression modeling explained 1.7% of the variation in femoral 
neck vBMD after accounting for age, clinic, population sub-structure, height and weight.   
Four SNPs in four genes (GHSR, rs558572; SOX6, rs1354329; LRP6, rs4477532; TBX3,  
rs6489968) had significant associations with lumbar spine vBMD in both the discovery and 
validation sample but the direction of the association was in different directions (Figure 3-2b). 
For the lumbar spine, there were 13 SNPs in 7 genes (APC, BMPR1B, FOXC2, HOXA, 
IGFBP2, NFATC1, SOST) had a consistent direction of association in both genotyping samples 
(Table 3-4).    Each individual SNP explained 0.03%-0.89% of the variation in lumbar spine 
vBMD in the pooled sample.  The SNP explaining the most variation in lumbar spine vBMD was 
rs1877632 in the SOST gene region that explained 0.89% of the phenotypic variation in vBMD.  
Men with the less common AA genotype for rs1877632 had 6% higher lumbar spine vBMD than 
men with the more common GG and GA genotypes.   As in the femoral neck analysis, rs6594646 
and rs4705573 were in LD and rs6594646 was consequently dropped from the regression 
modeling of significant SNPs for lumbar spine vBMD.  In addition, two SNPs in HOXA 
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 (rs6951180 and rs6964896; r2=0.939 and D’=1.000) and two SNPs in BMPR1B (rs3796443 and 
rs1434536; r2=1.000 and D’=0.992) were in high LD and thus rs6964896 and rs1434536 were 
dropped from the regression modeling.  Collectively, the 10 replicated SNP associations in APC, 
BMPR1B, FOXC2, HOXA, IGFBP2, NFATC1, and SOST explained 3.5% of the variation in 
lumbar spine vBMD after accounting for age, clinic, population sub-structure, height and weight.     
3.5 DISCUSSION 
Though highly heritable, little is known about the genetic variants contributing to BMD variation 
in men and volumetric BMD in general(28,29).  The current study used a two-staged genotyping 
strategy to investigate the association between SNPs in 383 biologically defined candidate genes 
and volumetric BMD at the lumbar spine and femoral neck in a large sample of older men. We 
identified robust associations between SNPs in 11 genes and lumbar spine and femoral neck 
vBMD and these associations were validated in a separate sample of older men.  To our 
knowledge, associations between SNPs in APC, BMPR1B, DMP1, FLT1, HOXA, IGFBP2, 
NFATC1, and PTN and BMD have not yet been described.  We also confirmed a previously 
identified association between several SNPs in the sclerostin (SOST), and forkhead box C2 
(FOXC2) genes with vBMD (30-34).  Importantly, although two of the gene associations were 
shared between the femoral neck and lumbar spine, the majority were distinct for the femoral 
neck or lumbar spine.  These observations underscore the importance of measuring BMD at 
multiple skeletal sites in studies aimed at identifying osteoporosis susceptibility genes. 
Although most of the candidate gene associations identified were specific to either the 
femoral neck or lumbar spine, SNPs in the gene encoding adenomatous polyposis coli (APC) 
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 were associated with vBMD at both skeletal sites.  The minor alleles of both rs4705573 in the 5’ 
flanking region and rs6594646 in intron 1 of APC were associated with lower vBMD at both the 
femoral neck and lumbar spine.   These SNPs are not known or predicted to influence APC 
function or expression and may be in linkage disequilibrium with the causal variation.  More 
commonly known for its role in cancer biology, APC targets β-Catenin for degradation in the 
WNT signaling pathway, an important pathway in bone metabolism(35).  APC is expressed in 
osteoblasts and osteoclasts from adult human bone(36) and mice with osteoblast specific APC 
deletions have increased bone deposition to such a degree that the marrow space is reduced(37).  
A third SNP, rs459552, is a non-synonymous variant that is only associated with femoral neck 
vBMD in this study.  Located at codon 1822, this SNP converts an asparagine residue to a valine 
residue and has been identified in studies of familial adenomatous polyposis(38).  In addition to 
replacing a hydrophilic amino acid with a hydrophobic one, this SNP falls in the B-catenin down 
regulation domain of the protein and is potentially functional(38,39). 
 Two SNPS upstream of the homebox (HOXA) gene cluster in the 5’ flanking region of 
HOXA13 were also associated with vBMD at the femoral neck and lumbar spine. The minor 
allele of rs6951180 was associated with higher BMD at both the femoral neck and lumbar spine 
and the minor allele of rs6964896 was associated with higher vBMD at the lumbar spine.  The 
HOXA genes are sufficiently close to enable enhancer sharing and it is possible that SNPs in the 
5’ region of the gene cluster may directly or indirectly influence HOXA gene expression.  HOX 
genes encode a family of transcription factors best known for their role in body patterning during 
embryonic development.  Humans have 39 HOX genes organized into four clusters termed HOX 
A, B, C and D.  The HOXA genes are involved in the normal development of the axial skeleton 
and limbs(40). The role of HOXA genes in determining BMD is less well characterized, but 
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 HOXA10 contributes to osteoblastogenesis by regulating target genes for osteoblast 
differentiation and bone formation including RUNX2, alkaline phophatase, bone sialoprotein, 
and osteocalcin(41). Thus, at least HOXA10 has a role in promoting bone formation beyond its 
role in patterning the embryonic skeleton.  Activation of HOXA genes has also been described 
during fracture repair and a re-examination of HOXA gene function in adult bone and BMD 
regulation may be warranted(42).  
The four genes that were uniquely associated with femoral neck vBMD in this study are 
all plausible biological candidates.  DMP1 encodes dentin matrix protein 1, an extracellular 
matrix protein that regulates osteoblast gene expression and is critical for proper mineralization 
of bone matrix(43).  DMP1 null mice have impaired bone mineralization and mutations in DMP1 
are known to cause autosomal recessive hypophosphatemia, a disease that manifests as rickets 
and osteomalacia(44-46).  There is also evidence for a BMD quantitative trait locus (QTL) in 
mice (Bmd2) that encompasses the DMP1 gene(47,48).  FGFR2 encodes a transmembrane 
receptor for fibroblast growth factor which is involved in bone growth and development.  
Activating and dominant negative mutations in FGFR2 are associated with altered bone 
mineralization and familial cranial synostosis syndromes(49,50).  FLT1 encodes the cell-surface 
receptor for vascular endothelial growth factor that is involved in osteoclastogenesis and 
osteoblast differentiation(51-55).  FLT1 null mice have decreased bone mineral apposition and 
bone formation rates and lower trabecular bone volume(56).   Pleiotrophin (PTN), also called 
osteoblast-stimulating factor 1, is an extracellular matrix protein released by osteoblasts that 
recruits, promotes adhesion of and increases proliferation of osteoprogenitor cells(57,58).  PTN 
transgenic mice have greater bone calcium content by bone volume compared to controls(59).    
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  The five gene associations specific to vBMD at the lumbar spine are also plausible 
biological candidates.  Bone morphogenetic protein receptor, type IB (BMPR1B) encodes a 
receptor for BMPs, which are involved in osteoblast commitment and differentiation(60).  
Transgenic mice with a truncated form of BMPR1B  display reduced bone formation rates and 
BMD(60,61).  Evidence for a BMD QTL that contains the BMP1RB gene has been identified in 
mice(48).  FOXC2 encodes forkhead box C2, a member of the forkhead/winged helix 
transcription factor family that serves as a key regulator of embryogenesis. Mutant mice null for 
FOXC2 show defects in axial skeletogenesis(62).  A modest association between a promoter 
SNP in FOXC2 and vBMD of the radius was reported in a study of Japanese men and 
women(30). IGFBP2, which encodes an insulin like growth factor binding protein, is thought to 
target IGFs to bone, is associated with long bone growth and over-expression of this gene 
product results in shorter bones(63,64). Further, male Igfbp2 knockout mice have reduced 
cortical and trabecular bone due to thinner trabeculae than controls(65). Additionally, levels of 
circulating IGFBP2 are negatively correlated with BMD in postmenopausal women(66). Nuclear 
factor of activated T-cells 1 ( NFATC1) is a transcription factor induced by tumor necrosis factor 
superfamily, member 11 (RANKL) that is involved in both osteoclast and osteoblast regulation 
(67-69).  Mutations in SOST have been associated with sclerosteosis and Van Buchem disease 
and polymorphisms in SOST have been associated with normal variation in BMD (31-33).  Both 
rs851054 and rs851056 are predicted to lie in the promoter region of SOST and rs851054 is 
predicted to abolish a sex determining region Y (SRY) binding site whereas rs851056 is 
predicted to change a transcription factor binding site from the TAL1/TCF3 complex to c-MYC 
or RUNX1 (24,70).   
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 Several significant associations were observed in both the discovery and validation 
samples, but the direction of the association was different (BMP7, CDK6, CYP17A1, EGFR, 
GHSR, IGF1R, IRAK2, LRP6, PAX3, SOX6, TBX3).  CYP17A1 which encodes 17α-
hydroxylase/17,20-lyase, has been previously studied for its association with BMD.  Some 
studies have identified an association between a promoter variant (rs743572) in CYP17A1 and 
areal BMD, while others have detected no association, an interaction with BMI or an association 
with bone size but not density(71-75).  Although this promoter variant was not genotyped in our 
study it is in LD with the SNP identified in our investigation (D’=0.915 and r2=0.670).  A non-
synonymous coding polymorphism in LRP6 (rs2302685), the gene encoding low density 
lipoprotein receptor-related protein 6, has also been examined for its relationship with areal 
BMD.  One study identified an association with fracture risk and a modest association with 
vertebral body size in men, but no association with BMD was confirmed in a larger multi-center 
investigation although a modest association with vertebral fracture was observed in men(76,77). 
The non-synonymous coding polymorphism was genotyped, but not associated with vBMD in 
our study, but a more common intronic variant (rs4477532) was statistically significant (but not 
in a consistent direction) with lumbar spine vBMD in our study.  Although there was not 
consistent evidence for association in our study, these candidate genes may warrant further 
examination.  
We were unable to document an association with SNPs in several widely studied 
candidate genes (COL1A1, ESR1, LRP5, VDR) and vBMD in the current study.  Two recent 
genome-wide association studies have identified significant associations with variation near the 
LRP5 and ESR1 genes and areal BMD but did not confirm associations between SNPs in or near 
COL1A1 and VDR with BMD at a genome-wide level of significance (6,7).  There are several 
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 reasons why we may not have been able to replicate these associations.  First, our study includes 
only men, whereas many of the past candidate genes have focused largely on women.  In 
addition, most of these candidate gene investigations have used areal BMD as opposed to the 
vBMD measures used in our study.  Finally, our study had 70% statistical power to detect a SNP 
association that explained 1% of the variation in BMD in the screening stage at alpha = 0.01.  
Thus, we cannot exclude the possibility of a weaker association between SNPs in the ESR1, 
COL1A1, VDR, or LRP5 genes and vBMD at the femoral neck or lumbar spine in older men. 
Three of the SNPs associated in both the discovery and validation samples of our study 
were also genotyped in a recent genome-wide association study, but were not significant with 
areal BMD at either the hip or spine (p>0.05) (7).  Although not directly genotyped in our study, 
other SNPs in the gene regions associated with vBMD in our study (APC, BMPR1B, DMP1, 
FGFR2, FOXC2, HOXA, NFATC1 and PTN) also showed associations (p<0.05) in this genome-
wide association study but did not achieve genome-wide significance.  Most notably, rs11984297 
located just downstream of the HOXA13 gene was associated with both hip (p=0.0002) and 
spine (p=0.0014) BMD but this SNP is not in LD with rs6951180 (D’=0.216 and r2=0.015) or 
rs6964896 (D’=1.000 and r2=0.008) which were genotyped and associated with BMD in our 
study(7). 
The amount of phenotypic variation in vBMD explained by SNPs in the current study 
was small; 1.7% for the femoral neck and 3.5% for the lumbar spine.  Although small, the 
magnitude of these findings are comparable to recent genome-wide studies of BMD and other 
quantitative traits like height(6,7,78).  For example, in a recent genome-wide association study of 
areal BMD, 0.6% and 0.2%  of the phenotypic variation in lumbar spine and femoral neck BMD 
was explained by two SNPs in two genes(6).  Given the high heritability of BMD, much of the 
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 variation in BMD explained by genetic factors remains to be identified.  Future studies not only 
examining SNP associations, but also investigating insertion deletion mutations, copy number 
variants, rare variants (<5% MAF) and interactions between genetic factors and between genetic 
and environmental factors may explain more of the variation in BMD.  
Our study has potential limitations.  First, our reference SNP panel for tag SNP selection 
was based on Phase I of the International Haplotype Map Project (HapMap), and consequently 
does not provide as comprehensive a set of tag SNPs as current projects based on Phase II of 
HapMap.  However, the SNPs included in this analysis tagged an average of 64% of the SNPs 
with over 5% MAF in Phase II of HapMap with a mean max r2 of 0.97.  To put this in 
perspective, our tag SNP set captured 82% and 95% of the SNPs with MAF over 5%  in the 
HOXA and APC gene regions whereas a recent genome wide study of BMD examining over 
300,000 SNPs captured 68% and 74% for these gene regions(7).  Our analysis also focused on 
SNPs with a minor allele frequency (MAF) of ≥5% and potentially functional SNPs with a MAF 
of  ≥1% and thus cannot exclude the possible contributions of less common variants in the 
candidate genes that were investigated. Our study is also limited to Caucasian men aged 65 years 
and older and our results may not be generalizable to other ethnic groups or to women.  This is a 
cross-sectional analysis of vBMD in a population of men that are likely losing bone (femoral 
neck integral vBMD is 9% lower in the oldest compared to the youngest men) and could be 
confounded by differences in genes influencing peak BMD versus genes influencing bone 
loss(20).  Future studies including other volumetric traits including bone structural geometry and 
bone loss may give further insight into the genetics of osteoporosis in men.  Though some of the 
associated SNPs in the current study are predicted to be functional, none are known to influence 
gene expression or function and are likely in linkage disequilibrium with the causal variant(s). 
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 Additional genotyping in the gene regions of interest will be needed in this and in other 
ethnically diverse populations to refine the association signals and to inform future in vitro 
functional studies.      
Although limited to studying only older Caucasian men, this study provides the first 
large-scale assessment of the genetic contributions to a unique skeletal trait (QCT volumetric 
BMD), assessed and adjusted for potential population stratification, identified a number of novel 
and robust genetic associations by including a two-stage internal replication design and 
collectively, explained more of the phenotypic variance in BMD than other genetic association 
studies to date (6). This study identifies novel genetic associations and suggests that distinct 
genetic factors may contribute to lumbar spine and femoral neck BMD in older men.  Additional 
studies in women and other ethnic populations are needed to confirm and extend the present 
findings. 
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 3.7 TABLES AND FIGURES 
Table 3-1 Candidate genes screened for association with bone mineral density in the discovery sample. 
Gene symbols are presented by chromosome in order across the given chromosome. 
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 Table 3-2 Participant characteristics (Mean and Standard Deviation). 
*Significant difference between discovery and validation sample (p<0.001) 
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 Table 3-3 Replicated associations for femoral neck volumetric BMD. 
Additive and recessive models were tested for each SNP and the regression parameter and p-value from the 
most significant genetic model (additive ore recessive) is shown.   
add: p-value from the additive model; rec: p-value from recessive model 
a) Minor allele frequency in the pooled sample 
b) Adjustment 1: Age, clinic site, population sub-structure 
c) Adjustment 2: Age, clinic site, population sub-structure, height, body weight 
d) Amount of variation explained after adjusting for age, site, population sub-structure, height, body weight 
e) HOXA genes were tagged as a cluster.  They include HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, 
HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, HOXA13  
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 Table 3-4 Replicated findings for lumbar spine volumetric BMD. 
Additive and recessive models were tested for each SNP and the regression parameter and p-value from the 
most significant genetic model (additive ore recessive) is shown.   
add: p-value from the additive model; rec: p-value from recessive model 
a) Minor allele frequency in the pooled sample 
b) Adjustment 1: Age, clinic site, population sub-structure 
c) Adjustment 2: Age, clinic site, population sub-structure, height, body weight 
d) Amount of variation explained after adjusting for age, site, population sub-structure, height, body weight 
e) HOXA genes were tagged as a cluster.  They include HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, 
HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, HOXA13 
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Figure 3-1 SNP association results for femoral neck volumetric bone mineral density. 
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Figure 3-2 SNP association results for lumbar spine volumetric bone mineral density. 
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 4.1 ABSTRACT 
In contrast to conventional dual-energy X-ray absorptiometry, quantitative computed 
tomography measures trabecular and cortical volumetric bone mineral density (vBMD) 
separately.  Little is known about the individual genetic variants associated with these two bone 
compartments in humans, although both may be important for determining bone strength and 
osteoporotic risk.  In the current analysis, we tested the hypothesis that there are different genetic 
variants associated with trabecular and cortical vBMD at the femoral neck by genotyping 4608 
tagging and potentially functional single nucleotide polymorphisms (SNPs) in 383 bone 
metabolism candidate genes in 822 Caucasian men aged ≥65 years from the Osteoporotic 
Fractures in Men Study (MrOS).  Promising SNP associations were then tested for replication in 
an additional 1155 men from the same study.  We identified SNPs in 5 genes (IFNAR2, 
NFATC1, SMAD1, HOXA and KLF10) that were robustly associated with cortical vBMD and 
SNPs in 9 genes (APC, ATF2, BMP3, BMP7, FGF18, FLT1, TGFB3, THRB, and RUNX1) that 
were associated with trabecular vBMD.  Consistent with animal studies, these results suggest 
that genetic loci for cortical and trabecular volumetric BMD at the femoral neck may be to some 
extent unique for each bone compartment.  
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 4.2 INTRODUCTION 
Bone mineral density (BMD) is an established determinant of bone strength and osteoporotic 
fracture risk.  BMD assessed by conventional dual-energy X-ray absorptiometry (DXA) 
measures the total bone mineral content in a projected area (integral areal BMD) and cannot 
directly measure other skeletal features that may also contribute to bone strength, such as the 
relative amounts of cortical and trabecular bone.  In contrast, quantitative computed tomography 
provides a direct measure of cortical and trabecular volumetric BMD and both of these bone 
compartments may contribute to bone strength and fracture risk(1,2). 
BMD is a highly heritable complex trait that is under context specific genetic 
regulation(3).  For example, the individual genetic factors contributing to BMD variation may 
differ between women and men, between skeletal sites and between trabecular and cortical bone 
(4-11).  However, the vast majority of studies in humans have searched for genetic variants 
associated with DXA measures of areal BMD, and most have focused on women. To better 
understand the genetic determinants of compartment specific volumetric BMD (vBMD) in 
humans, we explored the association of common genetic variation in 383 bone metabolism 
candidate genes with cortical and trabecular volumetric BMD (vBMD) of the femoral neck in 
1977 men from the Osteoporotic Fractures in Men Study (MrOS).  
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 4.3 METHODS 
4.3.1 Genotyping Sample 
This study utilized a two-stage genotyping design with two independent samples of older 
Caucasian men.  Both genotyping samples were comprised of men from the Osteoporotic 
Fractures in Men Study (MrOS).  This study has been described extensively elsewhere, but in 
brief, MrOS is a prospective cohort study of skeletal health in 5,995 community-dwelling men 
age 65 and older(12,13).  Men were recruited into the study from 6 clinical centers across the 
United States.  At the time of entry into the study men were ambulatory and had at least one 
native hip. 
 The genotyping samples were comprised of MrOS participants that were Caucasian, had 
vBMD measurements at the femoral neck, did not report taking bone-altering medications 
(androgens, anti-androgens or oral corticosteroids) and did not report being on osteoporosis 
treatment.  The first phase of genotyping was carried out on a discovery sample which included 
822 Caucasian men with cortical or trabecular vBMD measures at the femoral neck.  These men 
were selected without regard to their BMD level from the Minneapolis and Pittsburgh clinic 
sites.  Promising SNP associations identified in the discovery sample were then tested for 
replication in a validation sample consisting of 1156 additional men from the four other MrOS 
clinic sites (Birmingham, Palo Alto, Portland and San Diego). 
Participant Characteristics 
 At the baseline visit, clinic staff obtained participant characteristics including age, 
medical history and medication by questionnaire. Height was measured by Harpenden 
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 stadiometer and weight was measured by balance beam scale with participants wearing light 
clothing and no shoes. 
4.3.2 Volumetric BMD 
Volumetric BMD (vBMD) of the femoral neck was measured using quantitative computed 
tomography (QCT).  To contain costs, only the first 65% of the MrOS cohort and ethnic 
minorities were referred for QCT scans.  Men having had a hip replacement were not eligible for 
a hip scan.  Those who received a QCT scan were similar to those who did not (14).   
To measure vBMD at the femoral neck, a QCT scan of the pelvic region (from the femoral head 
to 3.5 cm below the lesser trochanter) was acquired at settings of 80 kVp, 280 mA, 3-mm slice 
thickness, and 512 x 512 matrices.  Images were acquired using a GE Prospeed (Birmingham), 
GE Hispeed Advantage (Minneapolis), Philips MX-8000 (Palo Alto), Siemans Somatom +4 
(Pittsburgh), Philips CT-Twin(Portland), Toshiba Acquilion (Portland) site, or Picker PQ-5000 
(San Diego).  Differences between the clinic sites exist and are statistically adjusted for in all 
analyses.  
Each participant scan included a calibration standard of three hydroxyapatite 
concentrations (150, 75 and 0 mg/cm3).  Images were converted from the native scanner 
Hounsfield Units (HU) to equivalent concentration (g/cm3) of calcium hydroxyapatite contained 
in the calibration standard. Regions of interest (ROI) in the left proximal femur were identified in 
QCT images reformatted along the neutral axis of the femoral neck. The periosteal boundary of 
the femur was determined with a threshold-based region growing algorithm. Using this 
boundary, the cross-sectional area in each slice along the neutral axis of the femoral neck 
between the proximal femoral neck and the lateral edge of the trochanter was calculated, and the 
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 minimum and maximum areas were determined. The femoral neck ROI was defined as the 
portion of the neck extending from the slice with minimum cross-sectional area (medial 
boundary) to a point 25% of the distance toward the maximal cross-sectional area. Integral 
volume of the ROI was computed as the total volume within the periosteal boundary. A 
trabecular volume of the ROI was obtained by applying an erosion process to the integral volume 
to retain the same shape in a region fully contained within the medullary space. The cortical 
volume was then defined by applying a threshold of 0.35 g/cm3 to all voxels between the 
periosteal boundary and the outer boundary of the trabecular volume.  All QCT scans were 
transferred to the University of California at San Francisco for processing and central review. 
Volumetric BMD for trabecular and cortical compartments was computed over all voxels in the 
respective volumes.  In a group of postmenopausal women, coefficients of variation for the QCT 
analysis used ranged from 0.6%-3% for vBMD measures(15).  
4.3.3 Candidate Gene and Single Nucleotide Polymorphism (SNP) Selection 
Candidate genes for vBMD were identified using evidence from several sources including 
literature searches (Pubmed, www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed), evidence of gene 
expression in a normal human trabecular bone cells (Skeletal Gene Database, sgd.nia.nih.gov, no 
longer available; NCBI UniGene, www.ncbi.nlm.nih.gov/sites/entrez?db=unigene), genes with 
functions of interest such as “regulation of bone mineralization” or “skeletal development” 
(Entrez Gene, www.ncbi.nlm.nih.gov/sites/entrez?db=gene; Amigo, 
amigo.geneontology.org/cgi-bin/amigo/go.cgi), genes with a skeletal phenotype (Jackson 
Laboratory Mouse Genome, http://www.informatics.jax.org) and genes implicated in human 
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 skeletal disorders (Online Mendelian Inheritance in Man, www.ncbi.nlm.nih.gov/omim).  From 
these resources, 383 candidate genes were identified for genotyping(16).  
For the first phase of genotyping (discovery sample), publically available data were 
interrogated for SNP variation in the region surrounding the candidate gene.  This was 
accomplished by first creating a reference SNP panel of variants with a minor allele frequency 
(MAF) of at least 5% in Phase I of the International HapMap Project (www.hapmap.org) in the 
genomic region spanning 30kb upstream of the transcription start site and 10kb downstream of 
the candidate gene transcript (17). Tag SNPs were selected from this reference SNP panel using 
a pair-wise correlation method (r2 ≥0.80)(18).  Candidate genes located near each other on the 
chromosome were tagged as a unit spanning all loci of interest (such as IGFBP2 and IGFBP5 
which are located only 7.6kb from each other on chromosome 2).  In addition to tag SNPs, 
potentially functional SNPs that were non-synonymous coding variants, predicted to alter a 
putative transcription factor binding site in the promoter region, or a putative exon splice 
enhancer with MAF ≥1% were selected for genotyping.  These putative functional SNPs were 
selected using either PupaSNP (pupasuite.bioinfo.cipf.es/) or Promolign 
(polly.wustl.edu/promolign/main.html) (19,20).   
In the second phase of the project (the validation sample), promising SNP associations 
from the discovery sample were replicated.  Specifically, SNP associations with a p-value ≤0.015 
for either cortical or trabecular vBMD in the discovery sample were then genotyped in the 
validation sample.  Additionally, SNPs with a p-value ≤0.05 in a gene that also had a SNP with 
p-value ≤0.015 in the discovery sample were genotyped in the validation sample.  
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 4.3.4 Genotyping 
Genomic DNA was extracted from frozen whole blood specimens using the Flexigene protocol 
(Qiagen; Valencia, CA).  Genotyping in the discovery sample and the majority of genotyping in 
the validation sample was completed using the Illumina Golden Gate custom assay.  Blind 
duplicate samples and internal controls were included to ensure reproducibility.  For the 
discovery sample we observed 100% reproducibility among the 4 internal controls run on each 
plate and 99.9% reproducibility among the 37 duplicate participant samples.  In the validation 
sample, we observed 99.9% reproducibility among the 4 internal controls run on each plate and 
99.9% reproducibility among the 26 blind duplicate samples.  To ensure maximum genotyping 
completeness in the validation sample, loci of interest that could not be successfully genotyped 
using the Illumina Golden Gate assay were genotyped using one of two platforms: the TaqMan 
allelic discrimination assay system (Applied Biosystems, Foster City, CA) on a 7900HT Real-
time PCR instrument with probes and reagents purchased from Applied Biosystems or 
Sequenom MassARRAY iPLEX Gold technology (Sequenom, Inc; San Diego, CA) with PCR 
primers purchased from Invitrogen (Carlsbad, CA).  Participant samples were run in duplicate 
for these platforms and an average reproducibility of 99.8% and 99.9% was observed for 
TaqMan and Sequenom, respectively.    
Several participants’ samples were dropped from analysis because they had a low call 
rate (<85%) (N=14) or were highly correlated with another sample indicating relatedness (n=13).   
Before analysis of the discovery sample, 500 loci were dropped based on pre-defined quality 
control parameters.  Specifically, loci in the discovery sample with an observed minor allele 
frequency less than 1% (N=129), that did not conform to the expectations of Hardy-Weinberg 
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 equilibrium (P<0.0005; N=123) or that had a call rate (<85%; N=241) were excluded from 
statistical analysis.  
The mean SNP density for candidate genes included in the analysis was 1 SNP per 13 
kilobase pairs (kbp) (range: 1 SNP/3 kbp – 1 SNP/97 kbp).  Tagging SNPs were selected based 
on Phase I of the International HapMap Project.  Nevertheless, the 4108 SNPs successfully 
genotyped and included in our analysis (4608 attempted) tagged on average 64% of the SNPs 
with a MAF >5% in the more recent phase II of the International HapMap project (range per 
gene: 1%-100%).  Of the SNPs captured by our tag SNP set, the mean max r2 was 0.97.  
4.3.5 Statistical analysis 
Population stratification was initially assessed using the model-based clustering program 
Structure (21).  There was little evidence of population stratification, but we accounted for 
potential fine scale population sub-structure in subsequent analyses using a principal components 
method of analysis(22).  Uncorrelated SNPs (r<0.2) were used to calculate the principal 
components for the discovery, validation and pooled samples. 
Genetic analyses assumed both an additive and recessive model of inheritance.  
Specifically, linear regression was used to test for an additive association between the number of 
copies of the minor allele and vBMD.  Regression methods were implemented for the recessive 
model to test if individuals with two copies of the minor allele differed from those with the other 
genotypes.  For instances where a SNP had fewer than 10 individuals with the rare genotype, 
only the additive model was tested to minimize spurious findings based on small genotype 
specific sample sizes.  Analyses were adjusted for patient age, clinic site and the first principal 
component from the population sub-structure analysis.  SNPs significantly associated in both the 
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 discovery and validation sample (p<0.05) and having an association in the same direction for 
both genotyping samples (a positive or negative regression coefficient for both samples) were 
considered replicated findings.  Replicated SNP associations were examined further in the 
pooled sample of 1977 individuals from the discovery and validation samples.  In addition to the 
analyses described above, further adjustment for height and weight was conducted in the pooled 
sample to determine if body size attenuated the relationship between genotype and vBMD.  
Linear regression analysis was used to determine the amount of phenotypic variation explained 
by the significant replicated SNPs.  Correlation between individual SNPs in the model was 
assessed to minimize collinearity in the model.  For instances where SNPs in the model were 
highly correlated, the SNP with the most missing genotypes was dropped from the regression 
modeling. 
4.4 RESULTS 
The average age of the 822 men in the discovery sample was 73 years (range 65-100 years) and 
did not differ from the validation sample (Table 4-1).  Participants in the validation sample were 
slightly taller, weighed less, had a lower BMI and had lower cortical and trabecular vBMD at the 
femoral neck (p<0.001 for all). 
Of the 4108 SNPs genotyped in the discovery analysis, 191 SNPs in 72 genes were 
associated with cortical vBMD and were genotyped in the validation sample (Figure 4-1a).  Of 
these 191 SNPs, 7 SNPs in 5 genes were consistently associated with cortical vBMD in the 
validation sample (Figure 4-1b).  One SNP was identified in the IFNAR2 (rs2834160), NFATC1 
(rs177820) and SMAD1 (rs1874572) gene regions while two SNPs were identified in the HOXA 
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 cluster of genes (rs6951180 and rs6964896) and KLF10 gene region (rs3133287 and rs1434278).  
In addition, one SNP in IGF1R (rs3784606) and one SNP in TCF4 (rs7240986) were significant 
in both the discovery and validation samples, but the direction of the association was 
inconsistent.  
A pooled analysis was conducted to determine the amount of variation in cortical vBMD 
that each of the 7 significant SNPs explained (Table 4-2).  The most significant SNP association 
was with rs177820 in the NFATC1 gene region (p=4x10-4) which explained 0.5% of the 
phenotypic variation in cortical vBMD.  For this SNP, men with the less common GG genotype 
had 1.2% lower cortical vBMD than those with the AA genotype.   Additional adjustment for 
height and weight did not attenuate the relationship. 
Individual SNPs explained between 0.2% and 0.5% of the variance in cortical vBMD.  
Regression models were constructed to determine the amount of variation explained by all 
significant and replicated SNPs.  There was high linkage disequilibrium (LD) between the two 
SNPs in the HOXA gene region (rs6951180 and rs6964896; r2=0.691; D’=0.967) and the two 
SNPs in KLF10 (rs3133287 and rs1434278; r2=0.882; D’=1.000); thus, rs6964896 and 
rs1434278 were dropped from the regression modeling to minimize collinearity in the model.  
The 5 remaining SNPs in IFNAR2, NFATC1, SMAD1, HOXA and KLF10 explained 1.8% of 
the variance (adjusted r2) in cortical vBMD after accounting for age, clinic, population sub-
structure, height and weight. 
We also identified 255 SNPs in 75 genes that were associated with trabecular vBMD 
(Figure 4-2a).  We confirmed an association with 12 of these SNPs in 9 genes and trabecular 
vBMD in the validation sample (Figure 4-2b).  Specifically, associations with one SNP in ATF2 
(rs4972738), BMP7 (rs6127983), FGF18 (rs313543), FLT1 (rs1408245), TGFB3 (rs7149264) 
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 and THRB (rs1505289) and two SNPs in APC (rs459552 and rs4705573), BMP3 (rs2903746 
and rs6814223) and RUNX1 (rs2834676 and rs2834694) were replicated in the validation 
sample (Figure 4-2b).  In addition, SNPs in NTRK3 (rs6496469), SOX5 (rs2133345), TCF4 
(rs618869) and TCF7 (rs30496) were significantly associated with trabecular vBMD in both the 
discovery and validation samples but the direction of association was inconsistent between 
samples.    
Further analysis of the 12 consistently associated SNPs was conducted in the pooled 
sample.  The most significant SNP association for trabecular vBMD was with rs2834694 in 
RUNX1 (p=5.3x10-6) which explained 1% of the variance in trabecular vBMD.  Individuals 
with the less common AA genotype had a 14% higher trabecular vBMD than men with the CC 
genotype.  Statistical adjustment for height and weight in addition to age, clinic and population 
sub-structure did not significantly attenuate the association between the 12 replicated SNPs and 
trabecular vBMD (Table 4-3). 
Each of the 11 replicated SNPs individually explained between 0.3 and 1.0% of the 
variation in trabecular vBMD.  None of the 12 replicated SNPs were highly correlated (even 
those in the same gene region) and all were entered into a regression model.  After accounting 
for age, clinic, population sub-structure, height and weight, these 12 SNPs explained 4.0% of the 
variation in trabecular vBMD. 
4.5 DISCUSSION 
Studies in humans and animal models suggest that the genetic determinants of trabecular and 
cortical BMD may differ but few specific loci have been identified for these bone strength 
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 related traits. The current study is the first, to our knowledge, to systematically investigate the 
association between common genetic variation in bone metabolism candidate genes and 
volumetric BMD in the trabecular and cortical bone compartments in humans.  We identified 
several genetic variants that were associated robustly with cortical or trabecular vBMD at the 
femoral neck in a large cohort of older Caucasian men.  Specifically, 7 SNPs located in 5 gene 
regions were consistently associated with cortical vBMD and 12 SNPs in 9 genes were 
consistently associated with trabecular vBMD in two independent samples of men from the same 
study cohort.  No SNP consistently associated with one bone compartment was also associated 
with the other compartment in this analysis.  These results suggest that loci for cortical and 
trabecular volumetric BMD at the femoral neck may be, at least to some extent, unique for each 
bone compartment.   
To the best of our knowledge, associations with SNPs in IFNAR2, SMAD1 and KLF10 
and cortical vBMD have not been described previously.  IFNAR2 encodes a membrane receptor 
for type I interferons, interferon α and β(23).  Type I interferon signaling is important in 
osteoclast regulation and bone resporption (24,25).  The protein encoded by SMAD1 is a signal 
transduction molecule and transcriptional modulator of bone morphogenetic protein 
receptors(26).  Targets genes of SMAD1 stimulate osteoblast differentiation and mineralized 
matrix formation(27).  Krupple-like factor 10 (KLF10), also known as transforming growth 
factor beta (TGFB) inducible early growth response (TIEG), is expressed in osteoblasts and is 
induced by TGFB, bone morphogenetic proteins and epidermal growth factor(28).  KLF10 
expression in osteoblasts is critical for both osteoblast-mediated mineralization and osteoblast 
support of osteoclast differentiation (29,30). KLF10 knockout mice have decreased cortical bone 
thickness relative to wild-type controls and a significant decrease in osteocyte number (31). 
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 A few of the SNPs associated with cortical vBMD were also associated with integral 
volumetric BMD at the femoral neck in a previous analysis of this cohort(16).  For example, we 
observed an association between the rs6951180 variant in the Homeobox A (HOXA) gene 
cluster and femoral neck integral vBMD (16).  Both SNPs associated with cortical vBMD in this 
study (rs6951180 and rs6964896) lie upstream of the HOXA gene cluster in the 5’ flanking 
region of HOXA13.  The HOXA genes are transcription factors involved in the patterning of the 
limbs during development and these genes may also be reactivated during fracture repair(32).  
Little is known about the possible role of HOXA genes in bone metabolism and maintenance of 
BMD in adults.  Nevertheless, HOXA10, which lies approximately 45kb downstream of the 
SNPs associated in our study may contribute to osteoblastogenesis by regulating target genes for 
osteoblast differentiation and bone formation(33). 
The less common G allele of rs177820 in NFATC1 was associated with lower cortical 
vBMD in this investigation.  In our previous analysis, we identified a similar association of the G 
allele with lower lumbar spine vBMD but not femoral neck intergral vBMD (16). NFATC1 
encodes nuclear factor of activated T-cells cytoplasmic 1, a transcriptional regulator of osteoclast 
differentiation and osteoclastogenesis(34).  On the other hand, experiments in mice expressing a 
constitutively active NFATC1 suggest that it regulates bone mass by functioning in both 
osteoblasts and osteoclasts(35). 
We also identified a novel association between SNPs in ATF2 and trabecular vBMD.   
ATF2 encodes activating transcription factor 2, a transcription factor that binds to cAMP 
response elements (CREs) and stimulates CRE-dependent transcription.  The ATF family plays a 
role in the expression of skeletal-specific genes and skeletal tissue development(36).  ATF-2 may 
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 play a role in trabecular bone formation(37).   Indeed, ATF-2 knockout mice lack normal-
appearing trabeculae(38). 
SNPs in genes encoding bone morphogenetic proteins BMP7 and BMP3, were also 
associated with trabecular vBMD in our analysis.  Bone morphogenetic proteins (BMPs) direct 
skeletal patterning, chondrogenesis and bone formation(26).  BMP3 is one of the most abundant 
BMPs in bone and BMP3 knockout mice have twice the trabecular bone as their wild-type 
littermates(39,40).  BMP7 increases bone formation by promoting osteoblastic differentiation 
and clinical studies have demonstrated efficacy of recombinant human BMP7 in the treatment of 
tibial fractures(41-43).     
A variant in the gene region encoding fibroblast growth factor 18 (FGF18) was also 
associated with trabecular but not cortical vBMD at the femoral neck.  FGF18 may have a direct 
effect on osteoblast development in trabecular bone and coordinate both chondrogenesis in the 
growth plate and osteogenesis in trabecular bone(44).  FGF18 null mice have delayed skeletal 
mineralization which is thought to be the result of delayed initiation of chondrocyte hypertrophy, 
decreased proliferation in the early stages of chondrogenesis, delayed skeletal vascularization 
and delayed osteoclast and osteoblast recruitment to the growth plate (45,46).     
We also observed an association between an intronic SNP in the gene encoding thyroid 
hormone receptor beta (THRB) and trabecular vBMD.  Thyroid hormone regulates bone 
turnover and mineralization in adults and is essential for skeletal development.  Thyroid hormone 
action is mediated by thyroid hormone receptors, which act as hormone inducible transcription 
factors to regulate expression of thyroid hormone-responsive target genes.  Although thyroid 
hormone receptor alpha appears to be the predominant hormone receptor in bone, mRNA and 
protein for thyroid hormone receptor beta are present in growth plate chondrocytes and 
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 osteoblasts at sites of endochondral and intramembranous ossification(47-50).  Furthermore, 
juvenile thyroid hormone receptor beta knockout mice have advanced endochondral and 
intramembranous ossification and increased bone mineral deposition, whereas adult animals 
have osteoporosis with reduced trabecular and cortical bone, reduced mineralization and 
increased osteoclast numbers and activity(51).  Thyroid hormone receptor beta is also critical for 
the determination of both the set-point of the hypothalamic pituitary thyroid axis and the levels 
of circulating thyroid hormones.  Thus, we are unable to conclude if the association of THRB 
polymorphisms and trabecular BMD in the current study might be mediated through direct 
skeletal actions of THRB or are indirectly mediated through circulating thyroid hormone levels. 
Two intronic SNPs in the gene encoding the runt homology domain transcription factor, 
RUNX1, were associated with trabecular vBMD.  The Runx family of transcription factors plays 
a fundamental role in organ development and cell differentiation. During skeletal development, 
Runx1 is thought to play a role in osteochondroprogenitor cell differentiation and in mediating 
early events of endochondral and intramembranous bone formation(52-54).  Polymorphisms in 
another Runx family member, RUNX2, have been associated with BMD and bone size but we 
are unaware of any previous reports of an association between RUNX1 SNPs and BMD (55-59).  
We were unable to confirm an association between RUNX2 SNPs and trabecular or cortical 
vBMD at the femoral neck in this study. 
The two variants in the gene encoding adenomatous polyposis coli (APC) (rs459552 and 
rs4705573) that were associated with trabecular vBMD in the present analysis were also 
associated with integral vBMD at the femoral neck in our prior analysis (16).  Adenomatous 
polyposis coli (APC) is involved in WNT signaling, is expressed in osteoblasts and osteoclasts, 
and mice with osteoblast specific APC deletion have increased bone formation(60-64).  The 
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 association with rs459552 is of particular interest since this is a non-synonymous variant that 
results in a change from an asparagine residue to a valine residue and has been identified in 
studies of familial adenomatous polyposis(65).  This SNP is located in the B-catenin down 
regulation domain of APC and could potentially regulate WNT signaling (65,66).  Similarly, a 
SNP in FLT1 (rs1408245) was associated with femoral neck trabecular vBMD in the current 
analysis and with femoral neck integral vBMD in our previous analysis (16).  FLT1 encodes the 
cell-surface receptor for vascular endothelial growth factor that is involved in osteoclastogenesis 
and osteoblast differentiation(67-71).  FLT1 null mice have lower trabecular bone volume which 
is consistent with our findings (72).  We also identified a SNP upstream of transforming growth 
factor beta 3 (TGFB3) that was associated with trabecular vBMD.  TGFB3 is involved in bone 
formation and increased levels of circulating TGFB3 have been associated with osteoporosis in 
women(73-75).  Although no association has been previously described between SNPs in 
TGFB3 and BMD, an intronic variant (rs2268624) was associated with ossification of the 
posterior ligament of the spine(76).   
The current findings are consistent with an emerging model whereby genetic loci for 
BMD may be at least to some extent specific for cortical and trabecular bone.  For example, 
genome-wide searches in mice have identified quantitative trait loci that may be distinctly 
associated with either cortical or trabecular vBMD (5,8).  Furthermore, family studies have 
found a low genetic correlation between trabecular and cortical vBMD suggesting different 
genetic contributions for each bone compartment (11).  Similarly, in the current investigation 
none of the replicated genes or SNPs that had consistent statistical associations were associated 
with both cortical and trabecular vBMD at the femoral neck.     
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 We were able to identify more genetic associations and explain a greater fraction of 
phenotypic variation for trabecular than for cortical vBMD.  It is possible that the genetic 
contribution to trabecular vBMD is greater than for cortical vBMD.  Indeed, heritability studies 
in humans report a lower heritability for cortical vBMD (17-42%) than for trabecular vBMD (59-
73%) but the average age of participants was younger than in our study (9-11).  However, the 
cortical rim of the femoral neck is thin and this may have increased measurement error and 
consequently decreased statistical power at this skeletal region.  Future studies of the 
appendicular skeleton in regions with a larger cortical area (for example, at the proximal tibia) 
may help to minimize this issue.  Our candidate gene selection was also based on several 
informatics resources, but nevertheless may have been biased towards genes influencing 
trabecular bone.  Future studies of genetic factors for trabecular and cortical vBMD that utilize 
hypothesis-free methods (such as genome-wide investigations) may yield further insight.  
SNPs in several additional genes were significantly associated with either trabecular or 
cortical vBMD in both the validation and discovery samples but the direction of the association 
was inconsistent (IGF1R, NTRK, SOX5, TCF4, TCF7). To our knowledge, only IGF1R has 
been investigated in prior candidate gene association studies of osteoporosis related 
phenotypes(77).  Although the evidence for these associations is not as strong, there are 
characterized biological scenarios for this phenomenon of different directions of association and 
these genes may warrant further examination(78,79).  
 We were unable to document an association between SNPs in several widely 
studied candidate genes (e.g., COL1A1, ESR1, LRP5, VDR) and trabecular or cortical 
volumetric BMD in the current study(80-83). Further, two recent genome-wide association 
studies identified significant associations with variation near the LRP5, RANKL, TNFRSF11B, 
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 ESR1, and WNT4 genes and BMD measured by DXA(84,85).  There are several reasons why we 
may not have been able to replicate these previous associations.  First, our study included only 
men, whereas these past studies have focused primarily on women.  In addition, most of these 
prior candidate gene studies measured integral areal BMD by DXA as opposed to cortical and 
trabecular volumetric BMD by QCT.  Finally, our study was able to detect a SNP association 
that explained at least 0.8% of the variation in BMD in the discovery sample with 80% statistical 
power at alpha = 0.05.  Thus, we cannot exclude the possibility of a weaker association between 
SNPs in or near the ESR1, COL1A1, VDR, TNFRSF11B, RANKL, WNT4 or LRP5 genes and 
volumetric BMD at the femoral neck in older men. 
Although the heritability of volumetric BMD is high (estimates range from 40-85%), the 
amount of phenotypic variation in vBMD explained by SNPs in the current study was small  
(1.7% for cortical vBMD and 4.0% for trabecular vBMD).  Although small, the fraction of 
variation explained by these SNPs is consistent with the effect size reported in recent genome-
wide association studies of skeletal related traits such as BMD and height (84-86).  For example, 
in a recent genome-wide association study of DXA measures of areal BMD, 0.6% and 0.2% of 
the phenotypic variation in lumbar spine and femoral neck BMD was explained by two SNPs in 
two genes(84).  Future studies may need to consider other types of polymorphisms such as 
insertion-deletion mutations, copy number variants, and rare SNPs (<5% MAF) as well as 
interactions between genes and environmental factors in order to better account for the 
phenotypic variation in vBMD.  
Our analysis focused on older Caucasian men and our findings may not be generalizable 
to other populations.  Additional genotyping in younger men, ethnically diverse populations and 
in women would be useful to further confirm and extend these SNP association findings.  
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 Tagging SNP selection was based on Phase I of the International Haplotype Map Project 
(HapMap) and more recent releases of the HapMap project (Phase II) would have provided a 
larger SNP reference panel to select tagging SNPs from. However, the SNPs selected for the 
current analysis captured 64% of the common SNPs (≥5% MAF) in Phase II of HapMap with a 
mean max r2 of 0.97.  We also cannot assess the impact that rare variants might have on 
trabecular and cortical vBMD in our study since we restricted our analysis to tagging SNPs with 
MAF ≥5% and potentially functional SNPs with a MAF of ≥1%.  Finally, it is unclear if the 
SNPs identified in the current analysis have functional consequences or are merely in linkage 
disequilibrium with the causal variant(s).  Additional studies will be needed to confirm and 
refine the current association signals and to identify the causal variants involved.   
In conclusion, this is the first large-scale investigation of the potential genetic 
determinants of cortical and trabecular volumetric BMD in humans at a clinically relevant 
skeletal site, assessed and adjusted for potential population stratification, and identified several 
novel and reproducible genetic associations using a two-stage internal replication design.  
Although additional studies are needed to confirm and extend our findings, the current analysis 
suggests that the genetic factors contributing to cortical and trabecular volumetric BMD among 
older men may be at least to some extent unique for each bone compartment. 
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 4.7 TABLES AND FIGURES 
 
Table 4-1 Characteristics of genotyping samples. 
 
*Significant difference between discovery and validation sample (p<0.001) 
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 Table 4-2 Significant SNP associations with cortical volumetric BMD at the femoral neck. 
 
Additive and recessive models were tested for each SNP and the regression parameter and p- 
value from the most significant genetic model (additive or recessive) is shown.    
add: p-value from the additive model; rec: p-value from recessive model  
a)Minor allele frequency in the pooled sample  
b)  Adjustment 1: Age, clinic site, population sub-structure  
c)  Adjustment 2: Age, clinic site, population sub-structure, height, body weight  
d) Amount of variation explained after adjusting for age, site, population sub-structure, height, body weight  
e) HOXA genes were tagged as a cluster.  They include HOXA1, HOXA2, HOXA3,  
HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, HOXA13  
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 Table 4-3 Significant SNP associations with trabecular volumetric BMD at the femoral neck 
 
Additive and recessive models were tested for each SNP and the regression parameter and p- 
value from the most significant genetic model (additive or recessive) is shown.    
add: p-value from the additive model; rec: p-value from recessive model  
a)Minor allele frequency in the pooled sample  
b)  Adjustment 1: Age, clinic site, population sub-structure  
c)  Adjustment 2: Age, clinic site, population sub-structure, height, body weight  
d) Amount of variation explained after adjusting for age, site, population sub-structure, height, body weight  
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 5.1 ABSTRACT 
The WNT/ß-catenin Signaling Pathway is important in skeletal development and bone 
regeneration throughout the lifespan.  A number of associations between genetic variation in 
WNT pathway members and bone mineral density (BMD) have been identified, but little is 
known about how interactions between WNT pathway genes or between WNT pathway genes 
and the environment influence BMD.  In this study, 148 SNPs in 28 WNT pathway members 
were interrogated for significant gene-gene and gene-environment interactions with volumetric 
BMD at the lumbar spine and femoral neck in a sample of older Caucasian men from the 
Osteoporotic Fractures in Men Study (MrOS).  Specifically, interactions between SNPs and 
physical activity and interactions between SNPs and body weight were examined because of the 
hypothesized role of WNT signaling in the skeletal response to mechanical loading.  An 
interaction between a SNP in SFRP4 (rs2722303) and body weight was associated with lumbar 
spine volumetric BMD.  A previously reported interaction between physical activity level and 
SNPs in LRP5 with BMD was also confirmed.  In addition, a number of interactions between 
genotypes in WNT pathway genes were identified for both the lumbar spine and femoral neck.   
Although additional work is needed, these findings underscore the importance of evaluating 
genetic variation in the context of other genes and the environment when evaluating the genetic 
basis for BMD. 
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 5.2 INTRODUCTION 
The WNT/ß-catenin signaling pathway is an important signal transduction pathway involved in 
skeletal development and post-natal bone accrual.  This pathway is thought to influence bone 
mineral density in a number of ways including the regulation of osteoblast differentiation and 
proliferation and the control of apoptosis in osteoblasts and osteoclasts(1-4). 
Evidence is also building that WNT signaling is involved in bone’s response to 
mechanical loading.  Mechanical loading increases osteoblast proliferation and activity to 
promote bone formation and to adapt to the strain put on the bone(5,6).  In vivo mouse models 
demonstrate prominent WNT signaling in the osteocytes, the cells thought to be the mechano-
sensors of bone(7).  Knockout mouse models for low density lipoprotein receptor-related protein 
5 (LRP5), an important co-receptor in WNT signaling, have a suppressed response to mechanical 
loading compared to control mice(8).    A study in humans observed statistically significant 
interactions between LRP5 variation and physical activity level on BMD (9).  
Linkage and genetic association studies first identified associations with variants in the 
LRP5 gene and familial low and high BMD conditions and later with normal variation in BMD 
(10-13).  Associations between genetic variation in a number of WNT pathway genes (including 
DKK2, FZD1, LRP1, LRP6, SFRP1, SOST, WNT3a and WNT10b) and bone mineral density 
have been subsequently reported(14-17).  Although population genetic studies of WNT pathway 
members are becoming more common, little is known about the role of epistatic (or gene-gene) 
interactions between WNT pathway members and BMD. 
In order to better understand how SNPs in WNT pathway members may interact with 
each other and with environmental factors, we systematically screened SNPs in 28 WNT 
pathway genes for interaction effects with each other and with indices of mechanical loading 
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 (i.e., physical activity, body weight) on volumetric bone mineral density (vBMD) in a population 
of older Caucasian men.  Since prior evidence of an interaction between physical activity level 
and LRP5 SNPs exists, an a priori analysis of this gene was completed.  
5.3 METHODS 
5.3.1 Study Population 
Participants were Caucasian men selected from the Osteoporotic Fractures in Men Study 
(MrOS).  Briefly, MrOS is a prospective cohort study of 5,995 community-dwelling men age ≥ 
65 from 6 clinical centers across the United States (18,19).  To be eligible for recruitment into 
MrOS, men had to be ambulatory and not have had bilateral hip replacement.   
Caucasian MrOS participants with volumetric bone mineral density (vBMD) that were 
not taking bone-altering medications (androgens, anti-androgens, oral corticosteroids or 
osteoporosis treatment) were selected as part of a two-phase, large-scale candidate gene 
study(20).  The first phase of genotyping was carried out on a discovery sample, which included 
862 Caucasian men with hip or spine vBMD measures that were selected without regard to their 
BMD level from the Minneapolis, MN and Pittsburgh, PA clinic sites.  SNPs showing promising 
findings for volumetric BMD traits of interest were tested for replication in a validation sample 
consisting of 1156 additional men from the four other MrOS clinic sites (Birmingham, AL; Palo 
Alto, CA; Portland, OR and San Diego, CA). 
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 5.3.2 Participant Characteristics 
At the baseline visit, participant characteristics including age, medical history and medication 
usage were recorded.  Height was measured by Harpenden stadiometer and weight was measured 
by balance beam scale with participants wearing light clothing and no shoes.   
Physical activity was measured using the Physical Activity Scale for the Elderly (PASE)(21).  
This is a validated scale that is designed to assess physical activity in epidemiological studies of 
participants 65 years of age and older.  PASE consists of 12 questions that assess the leisure, 
household and occupational activities over the previous week.  Each of the questions is weighted 
using participant report of the amount of time spent for each activity and previously derived 
weights from physical activity logs and motion sensor data (22). 
5.3.3 Gene and SNP Selection 
SNP variation in WNT pathway genes was identified from a previous candidate gene study(20).  
The previous study investigated 4608 SNPs in 373 genes in a discovery sample of 862 men. The 
4608 SNPs in the previous study were either tag SNPs selected to cover the common variation 
across the candidate gene region (including the transcript, 30kb upstream and 10kb downstream) 
or were potentially functional SNPs.  Tagging SNPs were selected using a pair-wise correlation 
method called Hclust (r2 ≥0.80)(23).   Potentially functional SNPs that were non-synonymous 
and had a minor allele frequency (MAF) >1%, putative exon splice enhancers and promoter 
variants (MAF >2%) were identified using either the PupaSNP (pupasuite.bioinfo.cipf.es/) or 
Promolign (polly.wustl.edu/promolign/main.html) databases (24,25).  Replication of the most 
promising SNPs (p <0.015 or p <0.05 and in the same gene region as a SNP with p<0.015) was 
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 completed in a second validation sample.  This validation sample consisted of 1156 Caucasian 
men from the Birmingham, AL; Palo Alto, CA; Portland, OR; and San Diego, CA  
The WNT pathway had been targeted for genotyping in this previous study.  148 SNPs in 
28 genes from the WNT pathway were genotyped in both the discovery and validation sample 
and were included in this analysis (Figure 1).  However, since only SNPs that had promising 
associations were included in the validation study, the WNT pathway members are not 
comprehensively tagged in this analysis.  Compared to Caucasian reference data from Phase 2 of 
the International HapMap Project, the SNPs in our analysis were able to cover an average of 
33.0% (range 4.4%-90.7%) of the common variation (MAF >5%) in the reference database 
(Table 5-1) (26).  
For LRP5, only four SNPs were genotyped in both the discovery and validation 
genotyping samples (rs312018, rs314756, rs634918, and rs676318).  Since an interaction effect 
of LRP5 genotype and physical activity on BMD was previously described, additional analysis 
of the 12 LRP5 SNP variants from the more comprehensive, discovery set of SNPs was 
conducted.  
5.3.4 Volumetric Bone Mineral Density 
Quantitative computed tomography (QCT) was used to measure vBMD of the central skeleton in 
a subset of men in the MrOS cohort.  Specifically, the first 65% of the cohort and all non-white 
men were referred for QCT scans.  QCT scans of the lumbar spine and pelvis were used to obtain 
vBMD for two anatomical regions of interest (ROIs); the second lumbar vertebra and the femoral 
neck.   
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 The lumbar spine scan was obtained from 5 mm above the L1 superior endplate to 5 mm 
below the L2 inferior endplate and the ROI included the entire second lumbar verebra excluding 
the transverse process.  The images were acquired using a setting of 120kBP, 150 mA, 1 mm 
slice thickness and 512x512 matrices.  The hip scan was obtained from the femoral head to 3.5 
cm below the lesser trochanter at settings of 80 kVp, 280 mA, 3-mm slice thickness, and 512 x 
512 matrix in spiral reconstruction mode.  The femoral neck ROI is from the minimum cross-
sectional area to the point 25% towards the maximum cross-sectional area where cross-sectional 
area was measured along the neutral axis.  The images were acquired on a GE Prospeed at the 
Birmingham clinic, a GE Hispeed Advantage at the Minneapolis clinic, a Philips MX-8000 at the 
Palo Alto clinic, a Siemans Somatom +4 at the Pittsburgh clinic, either a Philips CT-Twin or 
Toshiba Acquilion at the Portland site, and a Picker PQ-5000 in San Diego.  Differences between 
the clinic sites exist and are statistically adjusted for in all analyses.  QCT images were processed 
at the University of California at San Francisco using a standardized protocol.  Each participant 
scan included a calibration standard of three hydroxyapatite concentrations (150, 75 and 0 
mg/cm3) and these were used to convert between Hounsfield units and vBMD.  
5.3.5 Statistical Analysis 
Participant characteristics including age, physical activity, weight, height, BMI and vBMD were 
compared between the discovery and validation samples using analysis of variance.  Previous 
analyses of this data set have revealed little population stratification, yet we accounted for any 
fine scale population sub-structure by employing a principal components method calculated 
using uncorrelated SNPs (r <0.2) from the larger candidate gene study (27,28).   
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 The analyses of genotype interactions with physical activity were carried out using linear 
regression modeling that included terms for age, clinic, population sub-structure, SNP genotype 
(coded as the number of minor alleles), PASE score (continuous variable) and the multiplicative 
term between SNP genotype and PASE score.   The analyses for  genotype interactions with 
body weight were also carried out using linear regression modeling and these models included 
the terms for age, clinic, population sub-structure, height, SNP genotype (coded as the number of 
minor alleles), body weight and the multiplicative term between SNP genotype and body weight.  
For the systematic analysis of genotype-environment interactions, analyses were done in the 
discovery sample and statistically significant interactions (p<0.05) were replicated in the 
validation sample.  SNPs that were significant in both the discovery and validation sample and 
that had a consistent direction of association (i.e., having either a negative or positive regression 
coefficient for both the discovery and validation sample) were considered to be replicated.  
Replicated findings were further examined in the pooled sample of 2018 participants from the 
discovery and validation samples.  The replicated findings are presented graphically by genotype 
and tertile of body weight. 
Although genotype-environment interaction analyses were modeled in the same way, the 
full set of 12 LRP5 SNPs was only available in the discovery sample, so significant associations 
could not be replicated in the validation sample.  Significant interactions between PASE and 
LRP5 genotype were further graphed by genotype and tertile of physical activity.  Tertiles of 
PASE in the discovery sample were used for this analysis.  
Analysis of genotype-by-genotype interactions among WNT pathway genes was 
completed using regression modeling that included terms for both SNP genotypes  (coded as the 
number of minor alleles), the multiplicative interaction term between the two SNP genotypes, 
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 age, clinic and population sub-structure.  Analyses for genotype by genotype interactions were 
initially completed in the discovery sample and statistically significant interactions (p<0.05) 
were replicated in the validation sample.  Interactions that were statistically significant in both 
the discovery and validation samples (P<0.05) and that had a consistent direction of association 
were considered replicated. 
5.4 RESULTS 
There was no difference between the discovery and validation sample for PASE score (p=0.73), 
but men in the validation sample weighed less than men in the discovery sample (p <0.001) 
(Table 5-2).  Age was not different between the discovery and validation samples, but men in the 
validation were slightly taller, had lower vBMD at the femoral neck and lumbar spine (p<0.001). 
5.4.1 Interactions between WNT Pathway Members and Physical Activity and Body 
Weight 
Interactions between PASE physical activity score and the 148 SNPs in WNT pathway genes 
were tested for their association with integral vBMD at the femoral neck and lumbar spine.  In 
the discovery sample, 7 SNPs in 6 genes had significant interaction effects for femoral neck 
vBMD, but only one SNP (rs10488900 in DKK2) that had a significant interaction in the 
discovery sample (p=0.040) was also significant in the validation sample (p=0.027).  However, 
the direction of the association was not consistent in the two samples.  For the lumbar spine, 5 
SNPs in 4 genes had significant findings in the discovery sample, but only rs1420731 was also 
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 significant in both the discovery (p=0.048) and the validation sample (p=0.047) but the direction 
for this association was also not consistent.  
Interaction effects between body weight and the 148 SNPs in the WNT pathway genes 
were also examined for their association with integral vBMD at the femoral neck and lumbar 
spine.  10 SNPs in 6 genes had statistically significant interaction effects with weight for femoral 
neck vBMD in the discovery sample, but none of these associations were statistically significant 
in the validation sample.  For the lumbar spine, 9 SNPs in 7 genes had statistically significant 
interactions with body weight in the discovery sample.  One SNP in WNT5b (rs3926367) had a 
statistically significant interaction with body weight in the discovery (p=0.015) and validation 
samples (p=0.019) but did not have a consistent direction of association.  A SNP downstream of 
SFRP4 (rs2722303) showed a consistent statistically significant interaction effect with body 
weight on lumbar spine vBMD in the discovery (p=0.050), validation (p=0.031) and pooled 
samples (p=0.009).  Lumbar spine vBMD means from the pooled analysis adjusted for age, 
clinic, population sub-structure and height are presented by tertile of body weight and genotype 
for this SNP (Figure 2).  Higher body weight was associated with higher lumbar spine vBMD for 
the GG and GC genotypes, but weight was not associated with vBMD among men with the CC 
genotype (pairwise comparisons between tertiles within this genotype group are all >0.40).  
Furthermore, the C allele was associated with higher vBMD for those men in the lowest tertile of 
body weight (p= 0.005 for GG vs. CC genotype), but was not associated with vBMD in the 
second tertile of body weight (p=0.44 for GG vs. CC genotype) and the C allele was associated 
with lower vBMD for those men in the highest tertile of body weight (p=0.04 for GG vs. CC 
genotype). 
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 5.4.2 Interaction Effects of LRP5, Physical Activity and Body Weight 
Only four SNPs in the LRP5 gene were genotyped in both the discovery and validation sample.  
However, an interaction between SNPs in this gene and physical activity had previously been 
described; thus, we expanded our analysis to investigate all 12 of the LRP5 SNPs genotyped in 
the discovery sample (Figure 5-3) (9).  These 12 SNPs covered a much higher proportion of the 
genetic variation (52% coverage compared to Phase II of the HapMap Project) than the 4 SNPs 
genotyped in both the discovery and validation samples (14% coverage)(9).  Of the 12 LRP5 
SNPs, no SNP had a significant main effect association with vBMD using linear regression 
analysis to adjust for age and clinic.  
There were nominally statistically significant interactions between PASE score and LRP5 
SNPs (Figure 5-4A).  Specifically, there was a statistically significant interaction between PASE 
score and two SNPs in LRP5 (rs638051 and rs643892) with volumetric  BMD at both the 
femoral neck and lumbar spine.  Men with the common genotype (AA) of rs643892 had lower 
femoral neck (p=0.010) and lumbar spine (p=0.033) vBMD with increased physical activity, but 
men with the less common genotype (TT) had higher vBMD with increased physical activity 
(Figure 5-5).  A similar pattern was observed for rs638051 (Figure 5-6) with men possessing the 
common genotype (AA) having lower vBMD with increased physical activity and men with the 
less common genotype (GG) having higher vBMD with increased physical activity.   
Interactions between LRP5 SNPs and body weight were also examined (Figure 5-4b).  
Significant interactions between rs634918 and body weight and between rs312018 and body 
weight were observed for femoral neck vBMD (p=0.009 and p=0.045 respectively).  For lumbar 
spine vBMD, statistically significant interactions were observed between rs587397 and body 
weight (p=0.031) and between rs643892 and body weight (p=0.037).  Only rs643892 had 
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 statistically significant interactions with PASE score and body weight, but this statistically 
significant interaction was only observed for lumbar spine vBMD. 
5.4.3 Gene-Gene Interactions Between WNT Pathway Members 
In total, 9,887 pair-wise interactions between SNPs in 28 different WNT pathway genes were 
tested for integral vBMD in the femoral neck and lumbar spine.  Interactions were tested in both 
the discovery and validation samples.  In total, 23 pairs of SNPs in 19 pairs of genes had 
statistically significant interactions (p<0.05) in both the discovery and validation sample for 
femoral neck vBMD when adjusted for age, clinic and population sub-structure. Specifically, 22 
pairs of SNPs in 16 pairs of genes also had statistically significant interactions after adjusting for 
age, clinic and population sub-structure for lumbar spine vBMD (P<0.05).   These findings are 
summarized in Figure 5-7. 
There were a number of interactions that were statistically significant in both the 
discovery and validation samples, but that did not have a consistent direction of association.  For 
the lumbar spine and femoral neck combined, there were 17 of these SNP pairs that showed 
statistically significant but inconsistent associations.   
Consistent, replicated interactions were observed for both femoral neck and lumbar spine 
vBMD.   For the femoral neck, 15 SNP pairs within 11 pairs of genes were associated with 
vBMD when adjusted for age, clinic and population-substructure.  Nine of the SNP pairs (across 
7 pairs of genes) were statistically significant after additional adjustment for height and body 
weight.  One of the SNP pairs in the LRP5-DVL2 interaction (rs634918 and rs222851), the two 
SNP pairs in the WNT5A-LRP6 interaction (rs11918967 and rs4763794; rs11918967 and 
rs4477532), the WNT5A-KREMEN1 interaction (rs1191897 and rs134665), the SFRP2-SOST 
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 interaction (rs12645134 and rs1877632) and the FZD1-WNT11 interaction (rs6465306 and 
rs7933711) were no longer statistically significant after additional adjustment for height and 
body weight.  The statistically significant interactions for the femoral neck are presented in Table 
5-3. 
Statistically significant interactions were also detected for lumbar spine vBMD (Table 5-
4).  In the model adjusted for age, clinic and population sub-structure, 13 pairs of SNPs within 8 
pairs of genes were statistically significantly associated with vBMD.  All 13 pairs of SNPs 
remained statistically significant with additional adjustment for height and body weight. 
5.5 DISCUSSION 
We identified several statistically significant and novel interactions between WNT pathway 
genes and indices of mechanical loading as well as evidence of gene-gene interactions within the 
WNT pathway. In particular, we confirmed a previous observation that SNP variation in the 
LRP5 gene modifies the relationship between physical activity and bone mineral density(9).  
Although WNT pathway genes have received considerable attention for their importance in 
BMD variation among individuals, the current analyses suggest that genotypes in WNT pathway 
genes may have context specific effects on BMD. 
A statistically significant interaction between body weight and a SNP in the gene 
encoding secreted frizzled-related protein 4  (SFRP4) was associated with lumbar spine vBMD.  
SFRP4 is one member of a family of WNT pathway antagonists that bind WNT molecules to 
inhibit WNT signaling(29).  Experiments using a low bone mass mouse model indicate that 
recombinant SFRP4 inhibits osteoblast formation, and mice over-expressing SFRP4 in 
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 osteoblasts have suppressed bone formation, decreased bone mass and differences in trabecular 
micro-architecture(30,31).  Mechanical loading experiments in mice showed that expression of 
SFRP4 was not increased after mechanical loading in wild-type mice but was increased after 
loading in mice carrying a high bone mass mutation in the LRP5 gene(32).  Expression of other 
WNT pathway members (including WNT10b) was increased after mechanical loading in both 
wild-type and LRP5 mutant mice(32).  Although mechanical loading did not directly change the 
expression of SFRP4, it may change the expression pattern of WNT molecules. The statistically 
significant interaction between body weight and rs2722303 in SFRP4 could be part of a higher 
order interaction.  
Substantial evidence of genetic associations with SNPs in LRP5 and BMD 
exists(12,13,33), but there is conflicting information about the association of SNPs with BMD in 
older Caucasian men (9,20,34).  We did not detect an association with LRP5 SNPs and vBMD in 
older Caucasian men(20) which is consistent with the analysis of areal BMD completed by Kiel 
et al. (9). However, another large study of older Caucasian men detected a statistically significant 
association between LRP5 SNPS and BMD that was stronger in men than in women(34).  
Although all three of these populations are Caucasian, the van Meurs study is a European cohort 
while the other two are from the United States.  Differences in environmental exposures (such as 
average physical activity level over the lifespan) could be responsible for the differences 
between populations.  We detected a statistically significant interaction between physical activity 
and LRP5 SNPs as did Kiel et al.  We detected this interaction with two SNPs in intron 5 of the 
LRP5 gene, but the previous investigation observed an interaction between coding SNPs in exon 
10 and exon 18.  Additional evidence for the relationship between mechanical loading and LRP5 
exists in animal studies.  LRP5 null mice fail to increase bone mass in response to mechanical 
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 loading although they are able to recruit osteoblasts normally(8).  The interaction between 
physical activity and LRP5 genetic variation with BMD has been confirmed in two populations 
of older men and is supported by animal studies, but additional work is needed to understand the 
mechanisms underlying these interactions.  A comprehensive analysis including more LRP5 
variants and ethnically diverse populations of different ages will help clarify the relationship 
between physical activity and LRP5 in humans.  
We observed a number of gene-gene interactions for vBMD, but did not adjust for 
multiple comparisons.  With a type I error rate of 0.05 and 9,887 statistical tests in the discovery 
sample we would expect to observe 494 significant associations by chance.  Following up on 
those 494 findings with a type I error rate of 0.05, 25 significant associations would be expected 
by chance, which is comparable to the number of interactions we detected.  One of the most 
robust interactions was between an intronic SNP (rs6827902) in DKK2 and a SNP upstream of 
the SOST gene (rs1230399), which was statistically significant in both the discovery (p=0.004) 
and validation (p=0.028) analyses of femoral neck vBMD and explain 0.7% of the variation in 
the pooled sample (p=1x10-4).  DKK2 and SOST can both act as antagonists of WNT signaling 
by binding to the LRP5/6 co-receptor and may both modify the activity of the WNT signaling 
pathway(35-37).  Though additional investigation at both the population and functional level will 
be needed to confirm and characterize this relationship. 
This study does not include a comprehensive set of tagging SNPs for each gene, but does 
provide information on a broad range of WNT pathway members.  The 148 SNPs included in the 
analysis of gene-environment and gene-gene interactions were all associated with QCT 
measurements in the discovery sample and followed up on in the validation genotyping sample 
during previous main effects analyses.  Assessing interactions between SNPs with statistically 
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 significant main effects is a commonly employed strategy and has been used to study gene-gene 
interactions and BMD(38,39).   However, our analysis of LRP5 and activity interactions revealed 
that SNPs with no main effects on BMD may have statistically significant interaction effects on 
vBMD.   
While additional genotyping would have captured additional common variation in the 
WNT pathway genes, the additional statistical tests performed would have been amplified, 
especially in the gene-gene analysis that had almost 100 times the number of statistical tests as 
the gene-environment analysis.  Utilization of dimension reduction techniques to reduce the 
number of statistical tests will need to be assessed to help address this problem.  Hypotheses that 
incorporate functional evidence may also be helpful in assessing gene-environment and gene-
gene interactions.  
Much larger cohorts and replication samples will likely be needed to characterize gene-
environment and gene-gene interaction effects on bone mineral density.  However the LRP5-
PASE analysis serves as a useful illustration that simply increasing sample size may not aid in 
identification of interactions.  Kiel et al. reported an association with men but not women for this 
interaction and also showed evidence of different associations in different age groups(9).  
Replication samples that are comprised of different genders or that are ethnically diverse may 
complicate the biological relationships we hope to identify.  Our analysis was unique in that we 
tested interactions in two, highly comparable samples.   
Our follow-up analysis of the LRP5-PASE interaction was possible because both the 
current and previous analysis by Kiel et al. used a standardized and validated epidemiologic tool 
to measure physical activity(9).  In the future, careful consideration of measurement tools for 
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 environmental modifiers of genotype effects will be needed to ensure that comparisons can be 
drawn across populations and to help in collaborative efforts.  
Although not without limitations, the current analyses demonstrate that even in a 
biological pathway that is known to be important in regulating BMD, significant interactions 
between genes and between genes and the environment may influence BMD variation.  BMD is 
a highly heritable trait and genetic variants are thought to explain as much as 85% of the 
variance in this phenotype (40-44).  To date, little of the variation in BMD has been explained by 
analyses that consider genetic variants alone (45) and animal models indicate that interactions 
may explain an sizeable portion of the variation in BMD(46).   Advances in genotyping 
technology have allowed for higher throughput analysis of the relationship between genetic 
variants and BMD.  However, the current analyses demonstrate that not only increasing the 
number of genetic markers tested, but also understanding genetic variation in the context of other 
genes and the environment will be needed to unravel the complex relationship between genetic 
variants and BMD. 
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 5.7 TABLES AND FIGURES 
Table 5-1 Percent coverage and mean max r2 are calculated by comparing SNPs in the current analysis to 
SNPs with minor allele frequency greater than 5% in the CEU population from Phase 2 of the International 
HapMap Project. 
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 Table 5-2 Characteristics of Caucasian men included in the genotyping samples. 
 
* Statistically significant difference between means for the discovery and validation sample (p<0.001). 
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 Table 5-3 Replicated, consistent associations with femoral neck volumetric bone mineral density.  Analyses 
are adjusted for age, clinic and population sub-structure. 
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 Table 5-4: Replicated, consistent associations with lumbar spine volumetric bone mineral density.  Analyses 
are adjusted for age, clinic and population sub-structure. 
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Figure 5-7 Summary of gene pairs with significant genotype-by-genotype interactions with femoral neck and 
lumbar spine volumetric bone mineral density. 
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 6.0  GENERAL DISCUSSION 
6.1 SUMMARY 
Osteoporosis has been more carefully characterized in females since women bear much of the 
disease burden.  However, osteoporosis is a substantial public health problem in males and with 
the aging trend in the male population, osteoporosis is predicted to become an even larger health 
problem in older men.  BMD is used clinically to diagnose osteoporosis and research on the 
correlates of BMD has identified a number of demographic characteristics and environmental 
factors that influence BMD and osteoporosis risk.  Genetics is also a substantial contributor to 
BMD and the subject of much inquiry.  However, many questions remain to be explored. 
One area of interest is the heterogeneity between the major clinically relevant skeletal 
sites like the femoral neck and lumbar spine.    Though some genetic variants may influence 
BMD globally throughout the skeleton, others could be skeletal site specific.  To examine this 
hypothesis we studied SNPs in 383 candidate genes for associations with integral vBMD at the 
femoral neck and lumbar spine in two samples of older Caucasian men.  Statistically significant, 
consistent associations were identified for 8 SNPs in 6 genes for the femoral neck and for 13 
SNPS in 7 genes for the lumbar spine.  These genetic variants explained 1.7% of the phenotypic 
variation in femoral neck vBMD and 3.5% of the phenotypic variation in lumbar spine vBMD.  
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 The majority of the genetic loci identified were unique to one skeletal site, but two gene regions 
(HOXA and APC) were associated with both femoral neck and lumbar spine vBMD. 
Advances in bone imaging technology have allowed for images that can resolve both the 
trabecular and cortical bone compartments, butlittle is known about the genetic determinants of 
compartment specific BMD in humans. Statistical analysis between candidate genes and cortical 
vBMD at the femoral neck identified 7 SNPs in 5 genes that were consistently associated in both 
genotyping samples and explained 1.8% of the phenotypic variance.  Consistent associations in 
12 SNPs across 9 genes were identified for the femoral neck trabecular vBMD and these variants 
explained 4.0% of the phenotypic variation in trabecular vBMD.  This analysis did not identify 
any SNPs that were associated with both cortical and trabecular vBMD.  This, in combination 
with other findings, suggests the presence of genetic loci that are specific for each bone 
compartment[117-119, 121]. 
Much attention has been paid to understanding how individual genes and genetic variants 
influence BMD, but less is known about how genetic variants interact with each other and with 
environmental factors.  With this in mind, an analysis of gene-environment and gene-gene 
interactions in 148 SNPs from 28 genes in the WNT/B-catenin signaling pathway, an influential 
pathway for BMD, was conducted.  The WNT pathway is thought to be involved in mechanical 
loading[136] and mechanical loading is a major determinant of BMD.  Thus, interactions 
between genetic variants in WNT pathway members and both weight and physical activity were 
explored.  A statistically significant interaction between rs2722303 in the SFRP4 gene region 
and body weight was observed for lumbar spine vBMD.  This interaction was significant in two 
genotyping samples and displayed a consistent pattern of association.  Previous reports identified 
an interaction between SNPs in the LRP5 gene and physical activity[137], and our study was 
 140
 able to replicate these findings.  Finally, a number of statistically significant gene-gene 
interactions were identified between SNPs in different WNT pathway genes.  However, multiple 
testing is a concern for this analysis and further research is needed to verify these findings.  
Regression models for integral vBMD at the femoral neck and lumbar spine 
incorporating replicated main effects and replicated genotype-genotype and genotype-
environment interactions were carried out to evaluate the amount of phenotypic variation 
explained by factors identified in this analysis.  For the femoral neck, body weight, replicated 
genotype associations (Table 3-3) and replicated genotype-genotype interactions (Table 5-3) 
explained 7.9% of the phenotypic variation (adjusted r2) in the pooled sample after adjusting for 
age, clinic, height and population sub-structure. For the lumbar spine, body weight, replicated 
genotype main effects (Table 3-4), the interaction between rs2722303 in SFRP4 and body 
weight, and replicated genotype-genotype interactions (Table 5-4) explained 9.3% of the 
phenotypic variation (adjusted r2) in the pooled sample after adjusting for age, clinic, height and 
population sub-structure.  Although body weight explains a portion of the increase (1% for 
femoral neck vBMD and 2.5% for lumbar spine vBMD), including interactions in the model 
explains a higher proportion of the phenotypic variance and demonstrates the importance 
evaluating genotype-genotype and genotype-environemtn interactions 
6.2 STRENGTHS AND LIMIATIONS 
This study was conducted in a large population of older men from the general population and 
employed a two-stage design that allowed for statistical associations to be replicated in a separate 
but comparable sample.  The majority of genetics studies that have explored the genetics of 
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 BMD have been in women making this study unique.  However, this investigation was limited to 
studying older Caucasian men and the findings may not be generalizable to women, ethnic 
minorities or participants of younger ages. 
The study is also distinct because it explores the genetics of vBMD measured by QCT 
and not areal BMD measured by DXA.  QCT measurements of vBMD are not confounded by 
bone size and also allows for the trabecular and cortical bone compartments to be 
investigated[38].  In contrast, DXA measures integral areal BMD (trabecular and cortical BMD 
combined).  However, measures of vBMD are not commonly made in population based studies 
making comparison of findings with other reports of genetic associations more difficult. 
Although we employed a tagging SNP approach and also included potentially functional 
SNP variants, this study was designed using the first phase of the International Haplotype Map 
Project (HapMap).  Publically available databases have improved since this study was designed 
and a more comprehensive assessment of genetic variation in the candidate genes is now 
possible.  Additionally, this study was not designed to assess less common variants (MAF <5%) 
in the candidate genes that were investigated or other types of variants such as indels and 
structural variants.  Finally, the functional significance of the associated SNPs was not tested and 
is currently unknown. 
6.3 FUTURE DIRECTIONS  
Extending these findings to populations that include females and ethnic minorities could confirm 
these associations and determine their generalizability.  Although vBMD has many advantages it 
is a novel approach in population studies and is also costly. Therefore longitudinal measurements 
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 using this technique are not currently available.  The men in this association are older and likely 
actively loosing bone[98].  We cannot assess this active bone loss with the current, cross-
sectional data, and may be detecting genetic associations with volumetric bone loss. 
The cross-sectional nature of this analysis is also problematic when examining gene-
environment interactions. Longitudinal covariate data may give important insights.  For example, 
investigations of physical activity or weight change at midlife may be warranted. 
Finally, additional genotyping may help refine and confirm associations.  Fine-mapping 
of genetic associations may help pin-point causal variation that could be subsequently 
investigated in functional studies. 
6.4 PUBLIC HEALTH SIGNIFICANCE 
To better manage osteoporosis, improved prediction, prevention and treatment strategies are 
needed.  Genetic data has the potential to help in all three of these aspects. 
One of the essential public health services is to “evaluate effectiveness, accessibility, and 
quality of personal and population-based health services” which can be used to not only 
determine effectiveness of intervention programs but can also be used to retool existing 
intervention programs making them more effective[138].  Screening and clinical treatment 
protocols for osteoporosis are often reviewed and revised.  One area of contention is when to 
screen and treat older men.  A recent cost analysis identified two groups of men that should be 
screened using densitometry and treated if they have low BMD; men over age 65 with a previous 
fracture and those 80-85 years without a fracture history[139].  However, the authors contend 
that if treatment costs were to come down from $1,000 to $500, it would be cost-effective to 
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 screen men >70 years of age regardless of fracture history[139].  Genetic testing is not inherently 
expensive (a proposed high-throughput method for testing for two hemochromatosis risk alleles 
is priced at only $8.00 per test) and costs are likely to come down as technology continues to 
improve[140].  Although individual genetic variants that explain a large portion of osteoporosis 
risk have not yet been identified, it is plausible that genetic testing of less detrimental variants 
could be incorporated with patient characteristics (e.g., body weight) and traditional clinical 
assessment tools (e.g., DXA) to aid in clinical decision making for osteoporosis in controversial 
risk groups (e.g., men >70 with no fracture history).  In this context, genetics could aid in both 
the goals of prevention and prediction. 
 It is believed that pharmacogenomics, or the study of how genetic variation influences a 
patient’s drug response, will be an essential tool in individualized medicine[141].  This is most 
commonly thought of in terms of drug development, and our improved understanding of the 
biology of osteoporosis is already driving such discovery[142]. However, improved 
understanding of how genetic variants interact with other genes and with their environment may 
be important in developing public health interventions in addition to treatment strategies.  
Examples of genetic variants with differential responses to vitamin D supplementation and 
hormone replacement therapy in osteoporosis already exist[126]. For example, our analysis of 
the interaction between WNT pathway members and body weight not only refines the biological 
relationship between mechanical loading and the WNT pathway, but could be a potential avenue 
for public health intervention.  While obesity is a serious public health problem, low body weight 
in older populations is associated with frailty and morbidity[143].  Gene-environment 
interactions with body weight may have important public health Implications for lifestyle 
osteoporosis interventions.   
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 Although translation from research to clinical practice has been slow, there is great 
potential for genetics as a public health tool in the fight against osteoporosis. 
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 APPENDIX A 
LISTING OF GENES INCLUDED IN THE ANALYSIS 
Table A-1 Gene symbol, name and number of SNPs attempted and successfully genotyped for candidate 
genes. 
 
Row Labels Gene Name 
Number of 
SNPs 
Attempted 
for 
Discovery 
Sample 
Number of 
SNPs 
Passing 
QC for 
Discovery 
Sample 
Percent 
Cover-
age 
mean 
max 
r2 
ACVR2B Myostatin Receptor 4 4 72 0.984
ADIPOQ 
Adiponectin (adipocyte, C1Q 
and collagen domain 
containing) 8 6 41 0.972
ADIPOR1 adiponectin receptor 1 7 7 72 0.975
ADIPOR2_WNT5BCluster* 24 20 54 0.948
ADIPOR2 Adiponectin receptor 2     
WNT5B 
Wingless-type MMTV 
integration site family, 
member 5B     
AHSG Alpha-2-HS-Glycoprotein 12 11 66 0.954
AKT1 
v-akt murine thymoma viral 
oncogene homolog 1 8 6 87 0.964
AKT2 
v-akt murine thymoma viral 
oncogene homolog 2 5 3 57 0.966
ALOX15 
arachidonate 15-
lipoxygenase 9 6 61 0.952
ALPL 
Alkaline phosphatase, 
liver/bone/kidney 24 20 53 0.981
APC adenomatosis polyposis coli 10 10 75 0.954
AR Androgen Receptor 5 4 75 0.991
ARRB1 arrestin, beta 1 23 21 61 0.97
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 ARRB2 arrestin, beta 2 6 5 65 0.914
ATF2 
activating transcription factor 
2 10 10 89 0.968
ATF4 
activating transcription factor 
4 (tax-responsive enhancer 
element B67) 7 6 77 0.987
AXIN1 Axin 1 23 19 61 0.949
BAPX1 
bagpipe homeobox homolog 
1 (Drosophila) 6 5 48 0.939
BAX BCL2-associated X protein 15 13 68 0.962
BCL2 B-cell CLL/lymphoma 2 44 39 66 0.97
BDNF 
Brain Derived Neurotrophic 
Factor 11 10 78 0.957
BGLAP1 
Bone Gamma 
Carboxyglutamate Protein 1 
(aka Osteocalcin) 6 6 86 0.978
BGN Biglycan 4 1 0  
BMP2 
Bone Morphogenetic Protein 
2 13 12 38 0.979
BMP2K BMP2 inducible kinase 6 5 50 0.983
BMP3 
Bone Morphogenetic Protein 
3 10 8 83 0.952
BMP4 
Bone Morphogenetic Protein 
4 8 8 78 0.93
BMP7 
bone morphogenetic protein 
7 (osteogenic protein 1) 14 14 78 0.958
BMPR1A BMP Receptor, Type IA 15 15 91 0.977
BMPR1B BMP Receptor, Type IB 44 43 87 0.964
BMPR2 BMP Receptor, Type II 11 8 60 0.993
CALCA Calcitonin 4 3 78 0.967
CALCR Calcitonin Receptor 18 18 76 0.978
CASP2 
caspase 2, apoptosis-related 
cysteine protease (neural 
precursor cell expressed, 
developmentally down-
regulated 2) 8 5 84 0.996
CASP3 
caspase 3, apoptosis-related 
cysteine protease 5 4 62 0.974
CASP8 
caspase 8, apoptosis-related 
cysteine protease 7 7 75 0.945
CASR Calcium Sensing Receptor 3 3 5 0.99
CBFB 
core-binding factor, beta 
subunit 3 3 73 1
CCND1 cyclin D1 12 11 58 0.958
CDK6 cyclin-dependent kinase 6 20 18 81 0.942
CDKN1A 
cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 19 13 53 0.955
CDKN1C 
cyclin-dependent kinase 
inhibitor 1C (p57, Kip2) 16 12 27 0.974
CEBPA 
CCAAT/enhancer binding 
protein (C/EBP), alpha 6 5 71 0.994
CEBPB 
CCAAT/enhancer binding 
protein (C/EBP), beta 8 8 94 0.98
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 CER1 
Cerberus 1 homolog, 
cysteine knot superfamily 
(Xenopus laevis) 16 15 61 0.952
CHRD chordin 9 9 33 1
CHRDL2 chordin-like 2 12 9 55 0.955
CHUK 
conserved helix-loop-helix 
ubiquitous kinase 
(IKK1/IKKA) 6 6 82 0.94
CKTSF1B1 
gremlin 1, cysteine knot 
superfamily, homolog 
(Xenopus laevis) 11 9 64 0.937
CLCN7 chloride channel 7 20 17 31 0.994
CNTF ciliary neurotrophic factor 4 3 3 1
CNTFR 
Ciliary Neurotrophic Factor 
Receptor - a 14 13 62 0.95
COL1A1 
Type I Collagen, I alpha 1 
Chain 8 7 48 0.948
COMT 
Catechol-O-
Methyltransferase 18 15 51 0.971
CRH 
Corticotropin Releasing 
Hormone 4 4 96 1
CRHBP 
Corticotropin releasing 
hormone binding protein 9 9 51 0.971
CRHR1 
Corticotropin releasing 
hormone receptor 1 8 6 30 0.94
CRHR2 
Corticotropin releasing 
hormone receptor 2 14 12 56 0.972
CSF1 
Colony Stimulating Factor 1 
(macrophage) 19 16 56 0.962
CSF1R 
colony stimulating factor 1 
receptor 17 15 43 0.937
CSF2 
Colony Stimulating Factor 2 
(granulocyte-macrophage) 14 11 85 0.958
CSF2RB 
colony stimulating factor 2 
receptor, beta 12 10 71 0.96
CSF3 
colony stimulating factor 3 
(granulocyte) 10 8 83 0.979
CSF3R 
colony stimulating factor 3 
receptor (granulocyte) 18 12 43 0.982
CTGF 
connective tissue growth 
factor 13 13 55 0.957
CTNNB1 
catenin (cadherin-associated 
protein), beta 1, 88kDa 5 4 93 0.98
CTSK 
Cathepsin K 
(pycnodysostosis) 3 3 66 0.956
CYP11A1 
 Cholesterol Side-Chain 
Cleavage Enzyme 8 6 41 0.971
CYP11B1 
Cytochrome P450, family 11, 
subfamily B, polypeptide 1 16 6 96 0.902
CYP17A1  17a-hydroxylase/17,20-lyase 11 11 94 0.984
CYP19A1 Aromatase 21 19 49 0.973
CYP1A cluster*  7 6 69 0.955
CYP1A1 
cytochrome P450, family 1, 
subfamily A, polypeptide 1     
CYP1A2 cytochrome P450, family 1,     
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 subfamily A, polypeptide 2 
CYP1B1 
Cytochrome P450, Family 1, 
Subfamily B, Polypeptide 1 17 16 67 0.95
CYP21A2 
Cytochrome P450, Family 21, 
Subfamily A, Polypeptide 2 5 3 0  
CYP24A1 
Cytochrome P450, family 24, 
subfamily A, polypeptide 1 15 15 48 0.973
CYP27B1 
Cytochrome P450, family 27, 
subfamily B, polypeptide 1 5 4 10 1
CYP3A4 
Cytochrome P450, Family 3, 
Subfamily A, Polypeptide 4 4 3 66 1
DCN Decorin 6 5 91 0.998
DKK1 
dickkopf homolog 1 (Xenopus 
laevis) 7 7 62 0.933
DKK2 
dickkopf homolog 2 (Xenopus 
laevis) 15 14 73 0.979
DKK3 
dickkopf homolog 3 (Xenopus 
laevis) 16 14 35 0.94
DKK4 
dickkopf homolog 4 (Xenopus 
laevis) 4 4 90 1
DLK1 
delta-like 1 homolog 
(Drosophila) 10 8 60 0.975
DLL3 delta-like 3 (Drosophila) 8 7 83 0.987
DLX1_2Cluster*  14 14 8 1
DLX1 distal-less homeobox 1     
DLX2 distal-less homeobox 2     
DLX3 Distal-Less Homeo Box 3 7 7 75 0.984
DLX5 Distal-Less Homeo Box 5 7 6 50 0.96
DLX6 Distal-Less Homeo Box 6 6 4 17 0.93
DMP1 
dentin matrix acidic 
phosphoprotein 8 8 72 0.98
DNTTIP2 
deoxynucleotidyltransferase, 
terminal, interacting protein 2 
(estrogen receptor binding 
protein) 7 7 95 0.98
DVL1 
dishevelled, dsh homolog 1 
(Drosophila) 3 3 0  
DVL2 
dishevelled, dsh homolog 2 
(Drosophila) 9 8 95 0.975
E2F1 E2F transcription factor 1 5 4 78 0.993
EGF 
Epidermal Growth Factor 
(beta-urogastrone) 19 14 71 0.946
EGFR 
Epidermal Growth Factor 
Receptor 43 40 58 0.958
EGR2 
early growth response 2 
(Krox-20 homolog, 
Drosophila) 7 7 54 0.98
EGR3 early growth response 3 9 9 41 0.983
EN1 engrailed homolog 1 12 11 75 0.992
ENPP1 
ectonucleotide 
pyrophosphatase/phosphodie
sterase 1 23 21 64 0.984
ESR1 Estrogen Receptor Alpha 36 33 70 0.975
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 ESR2 Estrogen Receptor Beta 11 11 72 0.956
ESRRA 
estrogen-related receptor 
alpha 7 3 41 1
ETS2 
v-ets erthroblastosis vius E26 
oncogene homolog 2 (avian) 
[Homo sapiens] 19 18 61 0.978
EXT1 
exostoses (multiple) 1, 
exostosin 1 18 17 51 0.965
EXT2 
exostoses (multiple) 2, 
exostosin 2 14 13 74 0.958
FADD 
Fas (TNFRSF6)-associated 
via death domain 4 4 55 0.962
FBXO32 
F-Box Only Protein 32 (aka, 
Atrogin-1, MAFbx) 18 18 51 0.991
FGF1 Fibroblast Growth Factor 1 25 23 67 0.937
FGF18 Fibroblast growth factor 18 14 12 75 0.997
FGF2 Fibroblast Growth Factor 2 12 11 61 0.943
FGF23 fibroblast growth factor 23 10 8 38 0.934
FGF3 Fibroblast Growth Factor 3 11 7 29 0.961
FGFR1 
Fibroblast Growth Factor 1 
Receptor 13 12 84 0.956
FGFR2 
Fibroblast Growth Factor 2 
Receptor 63 55 59 0.967
FGFR3 
Fibroblast Growth Factor 3 
Receptor 5 4 66 1
FLT1 
fms-related tyrosine kinase 1 
(vascular endothelial growth 
factor/vascular permeability 
factor receptor) 35 33 60 0.965
FOS 
v-fos FBJ murine 
osteosarcoma viral oncogene 
homolog 15 15 64 1
FOSB 
FBJ murine osteosarcoma 
viral oncogene homolog B 10 7 41 0.972
FOSL1 FOS-like antigen 1 (Fra1) 2 2 81 0.967
FOXC2 
forkhead box C2 (MFH-1, 
mesenchyme forkhead 1) 12 10 58 0.949
FRZB Frizzled-Related Protein 12 11 51 0.971
FST Follistatin 9 8 36 0.983
FZD1 Frizzled homolog 1 6 6 65 0.977
FZD4 
frizzled homolog 4 
(Drosophila) 7 6 68 0.983
FZD5 
frizzled homolog 5 
(Drosophila) 6 5 40 0.973
FZD6 frizzled homolog 6 23 21 92 0.956
FZD7 frizzled homolog 7 9 9 52 0.993
GATA1 GATA binding protein 1 1 1 100 0.961
GATA2 GATA binding protein 2 9 8 62 0.989
GC Vitamin D Binding Protein 11 10 61 0.969
GDF5 
Growth differentiation factor 5 
(cartilage-derived 
morphogenetic protein-1) 5 3 92 0.989
GDF8 
Myostatin (Growth & 
Differentiation Factor 8) 5 5 56 0.961
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 GH1 Growth Hormone 7 4 76 0.922
GHR Growth Hormone Receptor 18 15 81 0.968
GHRH GH Releasing Hormone 5 4 27 0.992
GHRHR GHRH Receptor 13 10 52 0.963
GHSR 
growth hormone 
secretagogue receptor 9 9 69 0.958
GLI2 
GLI-Kruppel family member 
GLI2 32 31 57 0.968
GLI3 
GLI-Kruppel family member 
GLI3 34 32 44 0.96
GNRH1 
Gonadotropin Releasing 
Hormone 5 4 79 0.994
GNRH2 
Gonadotropin Releasing 
Hormone 2 9 8 45 0.983
GNRHR 
Gonadotropin Releasing 
Hormone Receptor 9 9 83 0.98
GNRHR2 
Gonadotropin Releasing 
Hormone Receptor 2 5 4 75 1
GPNMB 
glycoprotein 
(transmembrane) nmb 7 6 89 0.939
GPR24 
G protein-coupled receptor 
24 (melanin-concentrating 
hormone receptor 1, MCHR1) 6 5 28 0.976
GPR54 
G protein-coupled receptor 
54 5 5 54 0.992
GSK3B 
glycogen synthase kinase 3 
beta 14 13 57 0.972
HDAC3 histone deacetylase 3 15 15 39 0.975
HES1 hairy and enhancer of split 1 11 9 61 0.983
HEY1 
hairy/enhancer-of-split related 
with YRPW motif 1 10 10 51 0.977
HOXAcluster*  31 29 54 0.969
HOXA1 homeobox A1     
HOXA2  homeobox A2     
HOXA3 homeobox A3     
HOXA4 homeobox A4     
HOXA5 homeobox A5     
HOXA6 homeobox A6     
HOXA7 homeobox A7     
HOXA9 homeobox A9     
HOXA10 homeobox A10     
HOXA11 homeobox A11     
HOXA13 homeobox A13     
HOXDcluster*  28 26 78 0.962
HOXD1 homeobox D1     
HOXD3 homeobox D3     
HOXD4 homeobox D4     
HOXD8 homeobox D8     
HOXD9 homeobox D9     
HOXD10 homeobox D10     
HOXD11 homeobox D11     
HOXD12 homeobox D12     
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 HOXD13 homeobox D13     
HSD11B1 
Hydroxysteroid (11-Beta) 
Dehydrogenase 1 13 11 75 0.961
HSD17B1 
17b-Hydroxysteroid 
Dehydrogenase I 6 3 16 0.922
HSD17B2 
17b-Hydroxysteroid 
Dehydrogenase II 14 8 57 0.947
HSD17B3 
17b-Hydroxysteroid 
Dehydrogenase III 18 13 77 0.954
HSD17B4 
17b-Hydroxysteroid 
Dehydrogenase IV 13 12 76 0.956
HSD3B1 
3b-Hydroxysteroid 
Dehydrogenase I 4 3 92 0.971
HSD3B2 
3b-Hydroxysteroid 
Dehydrogenase II 5 4 85 0.958
IBSP 
Integrin-Binding Sialoprotein 
(aka, Bone Sialoprotein, 
Bone Sialoprotein II) 13 10 57 0.952
ID1 
inhibitor of DNA binding 1, 
dominant negative helix-loop-
helix protein 2 2 94 0.971
ID2 
inhibitor of DNA binding 2, 
dominant negative helix-loop-
helix protein 5 5 90 0.992
ID3 
inhibitor of DNA binding 3, 
dominant negative helix-loop-
helix protein 11 11 81 0.963
IFNAR1 
interferon (alpha, beta and 
omega) receptor 1 8 7 53 0.947
IFNAR2 
interferon (alpha, beta and 
omega) receptor 2 17 16 80 0.977
IFNB1 interferon, beta 1, fibroblast 6 6 56 0.994
IGF1 Insulin-Like Growth Factor I 14 13 72 0.961
IGF1R IGF-I Receptor 42 40 42 0.96
IGF2 Insulin-like growth factor 2 8 6 50 0.981
IGF2R IGF-II Receptor 38 30 75 0.981
IGFALS IGFBP, Acid Labile Subunit 5 4 48 0.928
IGFBP1_3Cluster*  12 10 32 0.963
IGFBP1 
Insulin-like growth factor 
binding protein 1     
IGFBP3 
Insulin-like growth factor 
binding protein 3     
IGFBP2_5Cluster*  18 18 48 0.969
IGFBP2 
Insulin-like growth factor 
binding protein 2     
IGFBP5 
Insulin-like growth factor 
binding protein 5     
IGFBP4 IGF Binding Protein 4 9 8 81 0.961
IGFBP6 IGF Binding Protein 6 5 4 50 0.957
IHH Indian hedgehog homolog 8 6 70 1
IKBKB 
inhibitor of kappa light 
polypeptide gene enhancer in 
B-cells, kinase beta 7 6 52 1
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 IKBKG 
inhibitor of kappa light 
polypeptide gene enhancer in 
B-cells, kinase gamma 2 1 66 1
IL1Cluster 
IL1 Cluster (IL1A and IL1B 
cluster) 20 17 85 0.972
IL1A      
IL1B      
IL1R1 IL1 Receptor I 19 18 77 0.968
IL1R2 IL1 Receptor II 12 12 79 0.983
IL1RN IL1 Receptor Antagonist 14 12 61 0.953
IL6 Interleukin 6 12 11 50 0.954
IL6R IL6 Receptor 10 10 69 0.975
IL6ST 
IL6 Signal Transducer (aka, 
gp130) 6 6 93 0.99
IRAK1 
IL1 Receptor-Associated 
Kinase 1 2 1 100 0.948
IRAK2_GHRLCluster
*  34 30 57 0.955
IRAK2 
Interlukin-1 receptor-
associated kinase 2     
GHRL 
ghrelin/obestatin 
prepropeptide     
IRAK3 
Interleukin-1 receptor-
associated kinase 3 11 11 60 0.952
IRS1 insulin receptor substrate 1 6 5 34 1
JAG1 jagged 1 16 12 52 0.957
KDR 
kinase insert domain receptor 
(a type III receptor tyrosine 
kinase) 15 14 69 0.944
KL klotho 17 16 60 0.962
KLF10 
TGFB inducible early growth 
response 10 10 30 0.997
KREMEN1 
kringle containing 
transmembrane protein 1 22 20 81 0.974
LCT lactase 8 3 45 0.956
LEF1 
lymphoid enhancer-binding 
factor 1 15 15 91 0.964
LEP 
leptin (obesity homolog, 
mouse) 8 8 79 0.956
LEPR leptin receptor 30 30 86 0.974
LHB Luteinizing Hormone Beta 6 4 31 1
LHCGR LH Receptor 29 27 53 0.963
LIF Leukemia Inhibitory Factor 15 12 65 0.989
LIFR 
Leukemia inhibitory factor 
receptor 15 13 70 0.902
LRP5 
LDL-Receptor-Related 
Protein 5 15 11 51 0.966
LRP6 
LDL-Receptor-Related 
Protein 6 19 19 79 0.968
LTBP1 
Latent TGFB Binding Protein 
1 51 45 24 0.952
LTBP2 
Latent TGFB Binding Protein 
2 21 20 70 0.955
LTBP3 Latent TGFB Binding Protein 5 5 61 0.982
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 3 
MAP2K1 
mitogen-activated protein 
kinase kinase 1 6 5 0 NA 
MAP2K2 
mitogen-activated protein 
kinase kinase 2 10 10 57 0.973
MAP3K1 
mitogen-activated protein 
kinase kinase kinase 1 12 12 86 0.984
MAP3K14 
mitogen-activated protein 
kinase kinase kinase 14 (NIK) 9 8 64 0.984
MAPK14 
mitogen-activated protein 
kinase 14, p38, p38 MAP 
kinase 18 17 64 0.992
MAPK3 
mitogen-activated protein 
kinase 3 4 4 53 0.968
MC2R 
Melanocortin 2 receptor 
(adrenocorticotropic 
hormone) 4 4 50 0.941
MEF2A 
MADS box transcription 
enhancer factor 2, 
polypeptide A (myocyte 
enhancer factor 2A) 10 9 41 0.96
MEF2B 
MADS box transcription 
enhancer factor 2, 
polypeptide B (myocyte 
enhancer factor 2B) 9 7 52 0.974
MEF2C 
MADS box transcription 
enhancer factor 2, 
polypeptide C (myocyte 
enhancer factor 2C) 12 12 64 0.978
MEF2D 
MADS box transcription 
enhancer factor 2, 
polypeptide D (myocyte 
enhancer factor 2D) 15 14 86 0.977
MEPE 
matrix, extracellular 
phosphoglycoprotein with 
ASARM motif (bone) 11 11 34 0.992
MGP Matrix Gla Protein 5 5 96 0.947
MMP9 
matrix metalloproteinase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 13 10 80 0.978
MSX1 MSH Homeo Box Homolog 1 10 7 45 0.958
MSX2 MSH Homeo Box Homolog 2 11 10 75 0.958
MYD88 
myeloid differentiation 
primary response gene (88) 6 4 60 0.992
MYFcluster*  11 11 87 0.983
MYF5 myogenic factor 5     
MYF6 myogenic factor 6     
MYOD1 MyoD (Myogenic Factor 3) 6 5 77 0.941
MYOG 
Myogenin (Myogenic Factor 
4) 2 2 80 0.986
NCOA1 nuclear receptor coactivator 1 13 11 74 0.96
NCOA2 nuclear receptor coactivator 2 21 20 86 0.988
NCOA3  Nuclear Receptor 17 16 88 0.985
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 Coactivator 3 
NFATC1 
nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 1 27 25 53 0.974
NFKB1 Nuclear Factor Kappa-B 15 12 86 0.937
NFKBIA 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, alpha (IKBA) 14 12 31 1
NFKBIB 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, beta 11 11 66 0.962
NOG Noggin 4 4 56 0.985
NOTCH1 Notch 1 20 17 57 0.994
NOTCH2 Notch 2 4 3 73 0.925
NR3C1 
nuclear receptor subfamily 3, 
group C, member 1 
(glucocorticoid receptor) 12 8 58 0.969
NR4A2 
nuclear receptor subfamily 4, 
group A, member 2 5 5 78 0.976
NRF1 nuclear respiratory factor 1 19 19 82 0.97
NTF3 Neurotrophin 3 11 10 60 0.981
NTRK1 
Neurotrophic tyrosine kinase, 
receptor, type 1 13 12 50 0.965
NTRK2 
Neurotrophic Tyrosine 
Kinase, Receptor, Type 2 17 17 41 0.973
NTRK3 
Neurotrophic tyrosine kinase, 
receptor, type 3 44 43 48 0.952
OGN OSTEOGLYCIN 5 4 96 0.962
OSCAR 
osteoclast-associated 
receptor 5 5 25 0.99
OSTF1 osteoclast stimulating factor 1 19 18 54 0.971
OSTM1 
osteopetrosis associated 
transmembrane protein 1 6 6 91 0.92
OSTN osteocrin 9 8 72 0.958
P2RX7 
purinergic receptor P2X, 
ligand-gated ion channel, 7 17 17 65 0.974
PAX1 paired box gene 1 2 2 60 0.984
PAX3 
Paired box gene 3 
(Waardenburg syndrome 1) 24 23 58 0.978
PAX7 paired box gene 7 24 21 40 0.979
PAX9 paired box gene 9 10 9 67 0.986
PDLIM4 PDZ and LIM domain 4 13 12 75 0.978
PHOSPHO1 phosphatase, orphan 1 8 7 73 0.985
PIK3R5 
phosphoinositide-3-kinase, 
regulatory subunit 5 12 12 70 0.979
POMC 
Proopiomelanocortin 
(adrenocorticotropin) 6 6 75 0.989
POSTN 
periostin, osteoblast specific 
factor 6 6 75 0.99
POU1F1 
POU domain, class 1, 
transcription factor 1 (Pit1, 
growth hormone factor 1) 10 9 87 0.981
PPARA 
peroxisome proliferative 
activated receptor, alpha 29 22 52 0.968
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 PPARD 
peroxisome proliferative 
activated receptor, delta 12 11 77 0.946
PPARG 
peroxisome proliferative 
activated receptor, gamma 19 17 83 0.97
PPARGC1A 
peroxisome proliferative 
activated receptor, gamma, 
coactivator 1, alpha 33 32 52 0.97
PPP3R1 
protein phosphatase 3 
(formerly 2B), regulatory 
subunit B, 19kDa, alpha 
isoform (calcineurin B, type I) 6 5 94 0.997
PROP1 
prophet of Pit1, paired-like 
homeodomain transcription 
factor 5 4 47 0.967
PTCH patched 6 6 80 0.956
PTGER4 
prostaglandin E receptor 4 
(subtype EP4) 4 4 76 0.964
PTH Parathyroid Hormone 3 3 84 0.97
PTHLH 
parathyroid hormone-like 
hormone 13 12 84 0.965
PTHR1 PTH Receptor 10 9 75 0.96
PTN pleiotrophin 26 24 66 0.965
RBL1 retinoblastoma-like 1 (p107) 6 6 96 0.982
RBL2 retinoblastoma-like 2 (p130) 9 5 67 0.99
RIPK1 
receptor (TNFRSF)-
interacting serine-threonine 
kinase 1 8 5 43 0.967
ROR2 
receptor tyrosine kinase-like 
orphan receptor 2 28 26 73 0.96
RPS6KA3 
ribosomal protein S6 kinase, 
90kDa, polypeptide 3 7 3 50 0.931
RUNX1 
runt-related transcription 
factor 1, CBFA2 60 56 60 0.953
RUNX2 
Runt-Related Transcription 
Factor (aka Core Binding 
Factor Alpha 1) 17 15 55 0.952
RXRA retinoid X receptor, alpha 16 15 75 0.963
RXRB retinoid X receptor, beta 8 7 62 0.958
RXRG retinoid X receptor, gamma 18 17 67 0.954
SFRP1 
secreted frizzled-related 
protein 1 12 12 81 0.946
SFRP2 
secreted frizzled-related 
protein 2 4 4 93 0.978
SFRP4 
secreted frizzled-related 
protein 4 17 14 50 0.964
SHBG 
Sex Hormone Binding 
Globulin 7 6 50 1
SHH Sonic hedgehog homolog 17 15 66 0.988
SHOX2 short stature homeobox 2 6 5 94 0.997
SMAD1 
SMAD, mothers against DPP 
homolog 1 10 10 93 0.952
SMAD2 
SMAD, mothers against DPP 
homolog 2 11 7 80 0.89
SMAD3 SMAD, mothers against DPP 27 25 53 0.96
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 homolog 3 
SMAD4 
SMAD, mothers against DPP 
homolog 4 4 3 100 0.993
SMO smoothened 10 9 52 1
SOST 
Sclerosteosis (aka, 
Sclerostin) 12 7 32 0.919
SOX4 
SRY (sex determining region 
Y)-box 4 3 3 75 1
SOX5 
SRY (sex determining region 
Y)-box 5 39 38 19 0.958
SOX6 
SRY (sex determining region 
Y)-box 6 27 27 52 0.981
SOX9 
SRY (sex determining region 
Y)-box 9 6 5 82 0.91
SP7 
Sp7 Transcription Factor 
(aka, Osterix, OSX) 3 3 64 0.934
SPARC 
secreted protein, acidic, 
cysteine-rich (osteonectin) 12 12 78 0.96
SPP1 
Secreted Phosphoprotein 1 
(aka, Osteopontin, Bone 
Sialoprotein I) 9 8 81 0.96
SRC 
v-src sarcoma (Schmidt-
Ruppin A-2) viral oncogene 
homolog (avian 20 20 81 0.98
STAR Steroidogenic acute regulator 3 3 100 0.955
STAT1 
signal transducer and 
activator of transcription 1, 
91kDa 16 15 57 0.95
STS Steroid sulfatase (STS) 8 3 75 0.979
TANK 
TRAF family member-
associated NFKB activator 13 11 86 0.985
TBX3 T-box 3 11 11 69 0.97
TBX2_4 Cluster*  25 22 70 0.961
TBX2 T-box 2     
TBX4 T-box 4     
TCF1 
transcription factor 1, hepatic 
nuclear factor (HNF1), 
MODY3 11 9 52 0.981
TCF4 transcription factor 4 49 48 81 0.971
TCF7 
transcription factor 7 (T-cell 
specific, HMG-box) 8 6 78 0.949
TCIRG1 
T-cell, immune regulator 1, 
ATPase, H+ transporting, 
lysosomal V0 protein a 
isoform 3 5 4 68 0.99
TGFB1 
Transforming Growth Factor 
b1 6 6 50 0.978
TGFB2 
Transforming Growth Factor 
b2 18 17 75 0.964
TGFB3 
Transforming Growth Factor 
b3 9 8 39 0.96
TGFBR1 TGFB Receptor I 8 7 88 0.966
TGFBR2 TGFB Receptor II 23 20 53 0.981
TGFBR3 TGFB Receptor III 42 39 68 0.97
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 THRA 
Thyroid hormone receptor, 
alpha 8 7 52 0.996
THRB 
Thyroid hormone receptor, 
beta 79 72 58 0.953
TLR4 toll-like receptor 4 11 10 65 0.97
TNFA Tumor Necrosis Factor Alpha 7 6 46 0.956
TNFAIP3 
tumor necrosis factor, alpha-
induced protein 3 (A20) 7 5 54 0.97
TNFRSF10A 
tumor necrosis factor 
receptor superfamily, 
member 10a (aka TRAILR) 18 17 79 0.959
TNFRSF11A Receptor Activator of NF-kb 14 13 44 0.983
TNFRSF11B Osteoprotegerin 14 14 53 0.991
TNFRSF1A TNFA Receptor I 10 9 70 0.955
TNFRSF1B TNFA Receptor II 25 24 69 0.991
TNFSF10 
tumor necrosis factor (ligand) 
superfamily, member 10 (aka 
TRAIL) 12 11 51 0.959
TNFSF11 Osteoprotegerin ligand 7 7 74 0.965
TOB1 transducer of ERBB2, 1 4 4 81 0.922
TRADD 
TNFRSF1A-associated via 
death domain 4 4 77 0.978
TRAF1 
TNF receptor-associated 
factor 1 6 5 90 0.99
TRAF2 
TNF receptor-associated 
factor 2 6 3 75 0.946
TRAF6 
TNF receptor-associated 
factor 6 13 8 96 0.972
TRH 
Thyrotropin-releasing 
hormone 1 1 1 1
TRPV5 
transient receptor potential 
cation channel, subfamily V, 
member 5 16 11 61 0.976
TSHR 
Thyroid stimulating hormone 
receptor 30 28 72 0.96
TWIST Twist homolog 1 5 4 57 0.965
TWIST2 Twist related protein 1 6 6 29 0.969
VDR Vitamin D Receptor 22 20 59 0.963
VEGF 
vascular endothelial growth 
factor 20 19 73 0.961
WDR5 WD repeat domain 5 1 1 0 NA 
WIF1 WNT inhibitory factor 1 6 6 85 0.946
WISP1 
WNT1 inducible signaling 
pathway protein 1 33 31 46 0.985
WISP2 
WNT1 inducible signaling 
pathway protein 2 6 6 67 0.943
WISP3 
WNT1 inducible signaling 
pathway protein 3 10 8 85 0.955
WNT10A 
wingless-type MMTV 
integration site family, 
member 10A 7 6 69 0.957
WNT11 
wingless-type MMTV 
integration site family, 
member 11 19 18 54 0.965
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 WNT3A 
Wingless-type MMTV 
integration site family, 
member 3A 7 7 94 0.977
WNT4 
Wingless-type MMTV 
integration site family, 
member 4 13 10 35 0.977
WNT5A 
Wingless-type MMTV 
integration site family, 
member 5A 11 10 32 0.982
WNT7A 
wingless-type MMTV 
integration site family, 
member 7A 14 11 44 0.934
WNT9A 
wingless-type MMTV 
integration site family, 
member 9A (aka, WNT14) 5 5 70 0.987
WNTCluster*  11 10 100 1
WNT1 
wingless-type MMTV 
integration site family, 
member 1     
WNT10B 
wingless-type MMTV 
integration site family, 
member 10B     
ZFP67 
zinc finger protein 67 
homolog (c-krox, kruppel-
related zinc finger protein 
hcKrox) 4 5 87 0.941
total  4608 4108   
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 APPENDIX B 
PATHWAY-BASED ANALYSIS 
Pathway based analysis was completed for genotyping done in the discovery sample for integral 
vBMD at the lumbar spine and femoral neck as well as for cortical and trabecular vBMD at the 
femoral neck.  This analysis was conducted using a gene-set enrichment methodology described 
by Wang et. al [144]. Though designed for genome-wide association studies, this methodology 
was used to assess if particular biological pathways are associated with vBMD.  Ingenuity 
Pathway Analysis software was used to define biological pathways (Table Appendix C-1).     
Nominal p-values, false-discovery rate and familywise error rate are presented for lumbar spine 
integral vBMD, femoral neck integral vBMD, femoral neck cortical vBMD, and femoral neck 
trabecular vBMD.  No biological pathways were significant after adjusting for multiple 
comparisons but the NFKB pathway was nominally associated with lumbar spine vBMD 
(p=0.049) and the IGF pathway was nominally associated with cortical vBMD (p=0.019). 
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 Table B-1 Pathway Definitions 
Pathway Name Pathway Member (gene symbol) 
  
PPAR ACDC, ADIPOR1, ADIPOR2, PPARA, PPARD, PPARG, PPARGC1A, MAPK14, 
MAP3K14, RXRA, MAP2K2, MAP2K1, MAPK3 
  
FGF FGF1, FGF18, FGF2, FGF23, FGF3, FGFR1, FGFR2, FGFR3, MAP3K1, MAPK14, 
MAP2K1, MAPK3 
  
BMP BMP2K, BMP3, BMP7, CHRD, FST, NOG, BMP2, BMP4, BMPR1A, BMPR1B, BMPR2 
  
Vitamin D CYP24A1, CYP27B1, GC, VDR, CEBPB, PTH, RXRB, RXRG, RXRA 
  
Steroid Hormone AR, COMT, CYP11A1, CYP11B1, CYP17A1, CYP19A1, CYP1A1, CYP1A2, CYP21A2, 
CYP3A4, ESR1, ESR2, ESRRA, GNRH1, GNRH2, GNRHR, GNRHR2, HSD17B1, 
HSD17B2, HSD17B3, HSD17B4, HSD3B1, HSD3B2, LHB, LHCGR, NCOA1, NCOA2, 
NCOA3, SHBG, STAR, STS 
  
Glucocorticoid CEBPA, CRH, CRHBP, CRHR1, CRHR2, CYP1B1, HSD11B1, MC2R, NR3C1, POMC, 
CEBPB 
  
TGFB ACVR2B, SMAD1, SMAD2, SMAD3, SMAD4, TGFB1, TGFB2, TGFB3, TGFBR1, 
TGFBR2, MAP2K2, MAP2K1, MAPK3 
  
WNT APC, AXIN1, CTNNB1, DKK1, DKK2, DKK3, DKK4, DVL1, DVL2, FRZB, FZD1, 
FZD4, FZD5, FZD6, FZD7, KREMEN1, LEF1, LRP5, LRP6, SFRP1, SFRP2, SFRP4, 
SMO, SOST, SOX5, SOX6, SRC, TCF4, WIF1, WISP1, WISP2, WISP3, WNT1, 
WNT10A, WNT10B, WNT11, WNT3A, WNT4, WNT5A, WNT5B, WNT7A, WNT9A, 
AKT1, AKT2, GSK3B 
  
IGF FOS, IGF1, IGF1R, IGF2, IGF2R, IGFALS, IGFBP1, IGFBP2, IGFBP3, IGFBP4, 
IGFBP5, IGFBP6, IRS1, MAP2K2, MAP2K1, MAPK3 
  
IL6 IL6, IL6R, IL6ST 
  
Parathyroid CALCA, CALCR, CASR, PTHLH, PTHR1, PTH 
  
Thyroid THRA, THRB, TRH, TSHR, RXRB, RXRG, RXRA 
  
Cell Cycle BAPX1, BAX, CASP2, CASP3, CASP8, CCND1, CDK6, CDKN1A, FADD, RBL1, 
RBL2, TANK, TNFRSF10A, TNFSF10, TRADD, CHUK, HDAC3, IKBKB, IKBKG, 
NFKB1, NFKBIA, NFKBIB, RIPK1, TNFA, TNFRSF1A, TNFRSF1B, TRAF2, GSK3B, 
MAP3K14, MAP2K2, MAP2K1, MAPK3 
  
IFN IFNAR1, IFNAR2, IFNB1, STAT1 
  
EGF EGR2, EGR3 
  
Calcium MEF2A, MEF2B, MEF2C, MEF2D, NFATC1, PPP3R1, ATF2, ATF4, HDAC3, MAPK3 
  
NFKB EGF, EGFR, GH1, GHR, IL1A, IL1B, IL1R1, IL1R2, IL1RN, IRAK1, IRAK3, MYD88, 
TLR4, TNFAIP3, TNFRSF11A, TNFRSF11B, TNFSF11, TRAF6, AKT1, AKT2, BMP2, 
BMP4, BMPR1A, BMPR1B, BMPR2, CHUK, IKBKB, IKBKG, NFKB1, NFKBIA, 
NFKBIB, RIPK1, TNFA, TNFRSF1A, TNFRSF1B, TRAF2, GSK3B, MAP3K14 
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 Table B-2 Pathway-based analysis for lumbar spine integral volumetric bone mineral density. 
Pathway Nominal P-value FDR P-value FWER P-value 
NFKB 0.049 0.373 0.319 
IGF 0.058 0.504 0.648 
WNT 0.139 0.500 0.794 
TGFB 0.107 0.412 0.817 
CellCycle 0.179 0.567 0.954 
IL6 0.238 0.622 0.981 
EGF 0.400 0.571 0.986 
BMP 0.312 0.708 0.997 
PPAR 0.405 0.837 0.999 
Calcium 0.420 0.781 0.999 
VitaminD 0.451 0.715 0.999 
FGF 0.515 0.775 1.000 
IFN 0.567 0.767 1.000 
SteroidHormone 0.612 0.777 1.000 
Thyroid 0.682 0.798 1.000 
Parathyroid 0.968 1.000 1.000 
Glucocorticoid 0.977 0.986 1.000 
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 Table B-3 Pathway-based analysis of femoral neck integral volumetric bone mineral density. 
Pathway Nominal P-value FDR P-value FWER P-value 
Calcium 0.054 0.542 0.413 
WNT 0.242 1.000 0.991 
IL6 0.362 1.000 0.998 
FGF 0.297 1.000 1.000 
IGF 0.412 1.000 1.000 
TGFB 0.488 1.000 1.000 
CellCycle 0.514 1.000 1.000 
Parathyroid 0.799 1.000 1.000 
PPAR 0.588 1.000 1.000 
VitaminD 0.764 1.000 1.000 
IFN 0.708 1.000 1.000 
SteroidHormone 0.682 0.992 1.000 
Glucocorticoid 0.883 0.983 1.000 
BMP 0.899 0.987 1.000 
Thyroid 0.898 0.992 1.000 
NFKB 0.854 0.932 1.000 
EGF 0.840 0.900 1.000 
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 Table B-4 Pathway-based analysis of femoral neck cortical volumetric bone mineral density. 
Pathway Nominal P-value FDR P-value FWER P-value 
IGF 0.019 0.176 0.163 
VitaminD 0.025 0.398 0.538 
IL6 0.444 1.000 0.996 
WNT 0.318 1.000 0.997 
TGFB 0.289 1.000 0.997 
BMP 0.284 0.954 0.997 
Calcium 0.335 0.936 0.998 
FGF 0.355 0.838 0.999 
Parathyroid 0.697 0.979 1.000 
CellCycle 0.559 1.000 1.000 
IFN 0.612 0.987 1.000 
Glucocorticoid 0.787 0.911 1.000 
NFKB 0.661 0.936 1.000 
Thyroid 0.773 0.933 1.000 
SteroidHormone 0.862 0.959 1.000 
PPAR 0.894 0.944 1.000 
EGF 0.970 0.943 1.000 
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 Table B-5 Pathway-based analysis of femoral neck trabecular volumetric bone mineral density. 
Pathway Nominal P-value FDR P-value FWER P-value 
WNT 0.078 0.636 0.479 
NFKB 0.102 0.564 0.703 
FGF 0.099 0.463 0.774 
CellCycle 0.149 0.490 0.896 
Calcium 0.192 0.691 0.986 
IFN 0.242 0.736 0.996 
EGF 0.482 0.651 0.996 
IL6 0.367 0.578 0.997 
PPAR 0.265 0.548 0.998 
BMP 0.266 0.529 0.999 
TGFB 0.357 0.592 1.000 
VitaminD 0.387 0.602 1.000 
IGF 0.425 0.583 1.000 
Parathyroid 0.727 0.663 1.000 
SteroidHormone 0.745 0.861 1.000 
Thyroid 0.787 0.855 1.000 
Glucocorticoid 0.879 0.972 1.000 
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